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Often considered the “big little problem,” postoperative nausea and vomiting (PONV) is a 
common surgical complication. Treatment of pain with opioids is the primary cause of PONV 
although other risk factors include female gender, non smoking status and history of PONV or 
motion sickness.  Research has focused on medications to prevent or treat PONV, and risk 
factors that contribute to PONV.  Genetics may also play a role.  The purpose of this study was 
to explore the association of CYP2D6 and µ-opioid receptor genotypes with PONV in patients 
with single extremity fractures.    
Subjects (n=143), aged 18-70 were recruited for this exploratory, descriptive study.  
Informed consent was obtained.  PONV was collected by self-report and chart audit. Saliva 
samples were collected for DNA extraction.   Results of Taqman® allele discrimination were 
used to assign a CYP2D6 classification of poor metabolizer (PM), intermediate metabolizer (IM) 
extensive metabolizer (EM) and ultrarapid metabolizer (UM). Two SNPS of the µ-opioid 
receptor gene were analyzed, A118G and C17T by Polymerace Chain Reaction (PCR).   Due to 
genetic differences within ethnic groups, only Caucasians   (n=112) were included in the 
CYP2D6 analysis.   The incidence of PONV in the PACU was 38%, increasing to 50% when 
assessed for 48 hours.  CYP2D6 classification results were: 7 (6%) PM group; 34 (30%) IM 
group; 71 (63%), EM group; and no ultrarapid metabolizers. Gender and history of PONV were 
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significant risk factors in this study (p<.05).  There was a trend for age (p=.071), but smoking 
was not significant (p=.505).  The CYP2D6 EM group served as the reference for binary logistic 
regression analysis which revealed a significant difference with the CYP2D6 PM group for 
presence of PONV (p =.003).   The sample size for the µ-opioid receptor genotype analysis was 
82, the genotype distribution was 58 (70%) AA or CC (wild type) and 24 (30%) polymorphism 
(AG, GG, CT, or TT were combined).   No statistical differences were found in the µ-opioid 
receptor genotype groups for PONV. Ultimately personalized medicine will allow health care 
providers to treat all patients individually, so it is important for clinical genetic research to 
identify those risks that may lead to a negative outcome.   
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1.0  INTRODUCTION 
Recently called the “big little problem” by several authors (Lichtor & Glass, 2008;  Nelson, 
2002), postoperative nausea and vomiting (PONV) is one of the most common and disturbing 
complications after surgery and general anesthesia (Apfel, Roewer & Korttila, 2002, and Gan, 
2007). The use of opioids for postoperative pain is recognized as the primary cause of PONV 
(Watcha & White, 1992).   PONV occurs primarily within the first 24 hours of surgery, may 
cause significant morbidity, delayed discharge from the post anesthesia care unit (PACU), 
increased length of hospital stay (LOS), increased hospital costs (Habib, Chen, Hu, & Gan, 2006; 
Mace, 2003) and perhaps most importantly in today’s world of health care; poor patient 
satisfaction (Silva, O’Ryan, & Poor, 2006; Myles, Williams, Hendrata, Anderson, & Weeks, 
2000).  Much research has focused on the use of combinations of medications to prevent or treat 
PONV, based on the multiple pathways that can cause PONV (Gan, 2007).  These new 
combination strategies have improved the management of PONV but have not eliminated the 
problem (Ho & Gan, 2006).  Other researchers have focused on identification of risk factors in 
order to predict which patients are most likely to experience PONV (Apfel, et al., 2008; White,  
O’Hara,  Robertson,  Wender, & Candiotti, 2008;  Murphy, Hooper, Sullivan, Clifford, & Apfel, 
C., 2006; Meng & Quinlan, 2006).  Despite volumes of research, the evidence continues to show 
that 20-30% of postoperative patients experience PONV (Kranke, Roewer, Smith, Piper, 
Wallenborn, & Eberhart, 2009). The emerging question becomes, are there genetic differences to 
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why patients respond so differently, and can these differences be identified?   Kranke and 
colleagues (2009) believe that instead of considering PONV the “big little problem,” that it 
should be viewed as a “big little opportunity.”  They believe that just as postoperative pain has 
come to be totally unacceptable, so should PONV.  This exploratory, descriptive study will 
provide pilot data for further research to determine the association between PONV, genetic 
variants and pain.   
1.1 PURPOSE 
The purpose of this study was to explore the association of CYP2D6 genotypes and µ−opioid 
receptor genotypes with PONV in adult patients admitted for surgery to repair a single, isolated 
orthopedic injury. 
1.2 SPECIFIC AIMS 
The primary aims of this study were: 
1.  To explore the association between CYP2D6 genotypes and PONV in patients admitted for 
orthopedic surgical repair of a single fracture to an extremity and to explore if CYP2D6 
genotypes moderate the relationship between the amount of opioids administered and the 
incidence of PONV 
2.   To explore the association between µ−opioid receptor genotypes and PONV in patients       
admitted for orthopedic surgical repair of a single fracture to an extremity and to explore if 
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µ−opioid receptor genotypes moderate the relationship between the amount of opioids 
administered and the incidence of PONV 
The secondary aims of this study were: 
3. To explore the association of CYP2D6 genotypes and the amount of rescue anti-emetics in the 
first 48 hours post-operatively in patients admitted for orthopedic surgical repair of a single 
fracture to an extremity 
4. To explore if patients who experience PONV report a higher level of pain than those subjects 
who do not experience PONV 
1.3 RESEARCH FRAMEWORK 
 
Figure 1: Diagram of the conceptual framework used for this study 
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1.3.1.1 PONV  
PONV is usually addressed in three different stages, nausea, retching and vomiting that occur 
within 24 hours of surgery. Some researchers designate the first two hours after surgery as early 
PONV as compared to later PONV that extends to the first postoperative day (Apfel et al., 2002).   
Nausea is defined as a subjective, personal feeling associated with awareness of the urge to 
vomit. Vomiting is defined as the forceful expulsion of gastric contents through the mouth 
(Watcha & White, 1992).   Retching is the muscular movement of the abdomen that precedes 
vomiting, and is also considered the non-productive vomiting (Habib, Chen, Taguchi, Hu, & 
Gan, 2007) that occurs when the stomach is empty.  For the purpose of this study, PONV is the 
combination of nausea and/or vomiting as measured by the need for rescue ondansetron.  
Ondansetron is the PRN anti-emetic of choice at the University of Pittsburgh Medical Center. In 
addition, because the PONV data was in some cases collected retrospectively, it was the only 
consistent way to determine if a patient had PONV on chart review. Two values for PONV were 
measured, the total amount received in the PACU and also total amount received 48 hours after 
surgery.  The time span of forty eight (48) hours was selected in order to have a more 
comprehensive picture of the PONV experience. It also allowed for a truer picture of PONV 
because all patients are given prophylactic ondansetron prior to leaving the operating room (OR) 
preventing some PONV that may have occurred in the PACU.  
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1.3.1.2 Postoperative opioids  
Total amount of opioids given during the procedure and in the PACU were recorded.  Amount of 
opioids were converted to morphine equivalence (Table 1) for comparison (McCaffery & Pasero, 
1999), and then adjusted by weight for the score used in this study. 
 
Table 1:  Morphine equivalents table used for definition of total opioids in study. 
Opioid             Dosage           Route 
Morphine 10 mg IV 
Morphine 30 mg PO 
Fentanyl 100ug IV 
Dilaudid 1.5 mg IV 
Dilaudid 7.5 mg PO 
Oxycodone 20 mg PO 
Oxymorphone 1 mg IV 
 
 
 
1.3.1.3 CYP2D6   
CYP2D6 is a member of the cytochrome P450 (CYP) superfamily, comprised of the most 
important drug-metabolizing enzymes. The CYP450 superfamily includes 57 functional CYP 
genes and 58 pseudo genes within 18 families. Members of the CYP family are exceptionally 
polymorphic and allelic variants result in a significant effect on drug metabolism. To date, the 
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gene CYP2D6, located on chromosome 22, has been the most extensively studied of the CYP 
enzymes, and is responsible for the metabolism of up to 25% of common medications (Zhou, S., 
2009).  Specifically, CYP2D6 can alter the metabolism of some opioids and is responsible at 
least in part, for the metabolism of many of the anti-emetic drugs given postoperatively, 
including ondansetron, tropisetron, palonosetron and dolasetron (Janicki, Schuler, Jarzembowski, 
& Rossi, 2006).  The CYP2D6 single nucleotide polymorphisms (SNPs) examined for this study 
are listed on Table 2. The SNPs listed were chosen for this study based on the high frequency in 
which they occur in North American populations. CYP2D6 classifications are assigned based on 
alleles identified. Individuals are considered poor metabolizers (PMs) when there are two 
nonfunctioning alleles, intermediate metabolizers (IMs) with two decreased functioning alleles 
or one non functioning allele and one allele that leads to decreased activity, extensive 
metabolizers (EMs) if two functional wild type alleles are present and ultrarapid metabolizers 
(UMs) in the presence of three or more functional wild-type alleles (Owen et al, 2009).    
Multiple gene copies will cause a patient to posses the extra functional wild-type alleles that 
usually leads to the UM classification. Increased metabolic activity leads to lower serum 
concentration of the drugs, leading to potential under-treatment. Conversely, a poor metabolizer 
may not clear the drug as easily and is at risk to develop toxic side effects due to prolonged 
plasma exposure.  However, depending on the drug, a poor metabolizer may not be able to 
metabolize medications into active metabolites, so they are also at risk for being under-
medicated.   
1.3.1.4 µ-Opioid Receptor Gene  
The genetic code for the µ-opioid receptor (OPRM1) is located on chromosome 6q24-q25.  
Mutations in OPRM1 are reflected in protein sequences in the µ receptors and have been 
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associated with variation in agonist binding. Two of the more clinically relevant polymorphisms 
that are associated with the OPRM1 gene were identified for the parent study.   They are A118G,  
a substitution that occurs in 10.5 to 18.8% of the population,  and C17T, a substitution that 
occurs in 1-10% of the population (Lötsch & Geisslinger, 2005).   Specifically, the 
polymorphisms include the A to G transition at nucleotide 118 (rs1799971) and the C to T 
transition at nucleotide 17 (rs1799972) (Bond et al., 1998).  Both of these single nucleotide 
polymorphisms (SNPs) are non-synonymous, resulting in amino acid differences.  Differences in 
genotypes are reflected in the protein structure and function of mu receptors, potentially 
influencing the ability of opioid binding.  
1.3.1.5 Ondansetron  
Ondansetron is the anti-emetic drug of choice at the University of Pittsburgh Medical Center.  A 
serotonin or 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, ondansetron has a well 
established role in the prophylaxis and the treatment of PONV.  Compared to earlier, more 
traditional anti-emetic medications, the 5-HT3 receptor antagonists have greater efficacy and 
fewer side effects (Ho & Gan, 2006).  Ondansetron, like most of the 5HT3 receptor antagonists, 
are more effective in preventing vomiting than nausea, but continues to be the first line of 
defense in both situations (Janicki, Schuler, Jarzembowski & Rossi, 2006).   Because it is the 
drug of choice, it has been selected as the measure to determine the presence of PONV in this 
study.  All postoperative patients are ordered ondansetron for relief of PONV.  It is not a routine 
medication order, but a “PRN” order, to be used in the event the patient experiences nausea and 
or vomiting.   
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1.3.1.6 Pain  
Pain is operationally defined for this study by an 11-point verbal pain rating score.  Subjects are 
asked to describe their pain with 0 designating no pain and 10 meaning the worst pain ever 
experienced.  A verbal pain score is considered more reliable when assessing postoperative 
patients in the Post Anesthesia Care Unit (PACU) who may be too drowsy to mark a line on a 
visual analog scale (Loos, Houterman, Scheltinga & Roumen, 2008; Cork, Isaac, Elsharydah, 
Saleemi, Zavisca, & Alexander, 2004).
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Table 2: Identification and definition of CYP2D6 alleles examined for this study 
Allele Name SNP Change Metabolic Activity Assignment  Notes 
CYP2D6*1   Reference allele  Normal Extensive Metabolizer 
Defined by absence of 
variation in other 
alleles  
CYP2D6*2 rs16947 1661G>C 4180G>C 
Normal, if multiple 
copies increased 
activity 
Extensive 
Metabolizer 
Ultrarapid 
Metabolizer if 
multiple copies  
CYP2D6*3 rs35742686 2549delA None  Poor Metabolizer   
CYP2D6*4 rs3892097 1846G>A None  Poor Metabolizer 
Most frequent allele - 
Caucasians 
CYP2D6*5   Whole gene deletion None  Poor Metabolizer    
CYP2D6*9 rs5030656 2615-2617del AAG Decreased  Intermediate  Metabolizer   
CYP2D6*10  rs1065852 100C>T and the absence of 1846G>A Decreased  
Intermediate  
Metabolizer 
As high as 50% in 
Asian populations 
CYP2D6*17 rs28371706 1023C>T Decreased  Intermediate  Metabolizer Marked variability 
CYP2D6*39 rs1135840 1661G>C 4180G>C Normal 
Extensive 
Metabolizer   
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1.4 BACKGROUND AND SIGNIFICANCE 
Postoperative nausea and vomiting has long been a concern for nurses caring for surgical 
patients. In the “Ether Days,” PONV was consistently as high as 80% (Watcha & White, 1992).  
Despite new medications, and new technology the incidence of PONV continues to be 20-30%, 
thus affecting as many as one third of the over 71 million surgical patients annually (ASPEN, 
2006).   PONV is one of the strongest predictors for prolonged hospital stay and unanticipated 
admission for outpatient surgical patients (Pradham, Crichton, Edmonds, (1999), costing what 
could account for millions of dollars of health care costs annually (Apfel, Kranke, & Eberhart, 
2004).   Potential adverse effects of PONV in addition to causing extreme discomfort for the 
patient can include aspiration, wound dehiscence, bleeding, hematoma, dehydration, electrolyte 
imbalance, delay in ability to begin oral medications, exhaustion and general delay in 
mobilization and recovery (Miaskowski, 2009; Jolley, 2001).  
1.4.1 Pathophysiology   
Essential to the central mechanism in the cause of PONV is the area postrema, a part of the brain 
that controls vomiting. It is located on the dorsal surface of the medulla oblongata at the caudal 
end of the fourth ventricle.  Because it lacks a blood-brain barrier, it detects toxins in both blood 
and cerebral spinal fluid (Gan, 2007).  The use of opioids for postoperative pain is recognized as 
being the primary cause of PONV (Watcha & White, 1992).  There are three different 
mechanisms that lead to PONV, all eventually stimulating the emetic center in the medulla.  
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First, opioids cause a reduced gastrointestinal mobility that generates a release of serotonin from 
the enterochromaffin cells in the gastrointestinal tract. The enterochromaffin cells produce 
approximately 90% of the body’s store of serotonin (Nielson & Olsen, 2008).  Serotonin then 
binds to the visceral 5HT3 receptors, stimulating vagal afferent neurons that in turn activate the 
vomiting center via the nucleus tractus solitarius (NTS) which is connected to the area postrema.  
Second, opioids stimulate the chemoreceptor zone in the brainstem, which causes a release of 
serotonin and dopamine, which directly activate the emetic center by binding to receptor sites 
(Gan, 2007; Nielson & Olsen, 2008).   A third mechanism develops when opioids enhance the 
sensitivity of the middle ear to movement.  This action activates the emetic center by the release 
of histamine and acetylcholine from vestibular fibers (Jolley, 2001; Silva et al., 2006).  Another 
neurotransmitter that has received attention in the past decade is Substance P, a member of the 
tachykinin family of neuropeptides (Gan, 2007).  Substance P may be released from 
enterochromaffin cells or from sensory neurons and is tied to at least three neurokinin 1 (NK1) 
subtypes that are located in the area postrema.  Currently, the mechanisms of NK1 activity are the 
focus of much research.   Blocking these multiple neurotransmitter receptor sites is the 
mechanism of most anti-emetic drugs, and many agents have been developed to act against one 
or more of these receptors (Nielson & Olsen, 2008).   Each of these pathways provides 
opportunities to reduce PONV as they all function independently.  Because of their 
independence, there is significant empirical evidence that support the use of multiple drugs to 
prevent or treat PONV.  Guidelines established by an expert panel recommends the use of 
combination therapy with 2 or 3 prophylactic  agents from difference classes for patients who are 
considered to be high risk for PONV (Gan et al., 2007).    
12 
   Not only is PONV the most common postoperative side effect (Apfel, Laara, Koivuranta, 
Greim, & Roewer, 1999; White et al., 2008), it is also the most bothersome for patients.  When 
patients are asked to identify the side effect they most want to avoid, they rank PONV above 
pain.  Macario and colleagues (1999) gave one hundred subjects play money to “buy” those 
symptoms they most wanted to avoid postoperatively.  The “winning” symptom, that symptom 
that patients were most willing to spend their money to prevent was vomiting.   In addition to 
vomiting, gagging on the endotracheal tube, incisional pain and nausea were the other top four 
symptoms that patients wanted to avoid, literally at all costs.  A decade later, Macario’s study 
was replicated in Germany and Turkey (Kerger et al., 2007).  In the second study, Kerger and 
colleagues gave 100 German and 100 Turkish patients 100 Euros to spend.  Patients were willing 
to spend their money to prevent PONV more frequently than pain or other postoperative 
complications.  Subjects who had not experienced PONV in the past spent an average of 68 
Euros to prevent postoperative vomiting.  However, patients who had experienced PONV in the 
past were willing to use all of their money to preventing PONV, using an average of 99 of 
the100 allotted Euros.  
1.4.2 Risk Factors  
Risk factors have been identified by multiple studies trying to predict those patients most 
vulnerable to develop PONV.  The risk factors most frequently identified include gender, 
smoking status, history of PONV or motion sickness and use of opioids for postoperative pain 
(White et al., 2008; Apfel et al., 2008; Murphy et al., 2006).   On the basis of two independent 
studies, Apfel and colleagues (1999) developed a simplified risk score for predicting PONV.  In 
a study of 1,137 subjects, they assigned one point for each risk factor known, so a non-smoking 
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female with a previous history of PONV that was treated with opioids for postoperative pain 
would be assigned a score of four.  Using forward stepwise regression, they found that the 
presence of none, one, two, three or four of these risk factors increased the incidence of PONV 
by 10%, 21%, 39%, 61%, and 79%, respectively.   The Risk Factor Assessment Tool has been 
further tested and continues to successfully give physicians and nurses the opportunity to provide 
guidance for prophylactic anti-emetic therapy, especially focusing on those patients who are 
considered high risk (Apfel, Korttila, et al., 2004; Apfel).  Silva and colleagues (2006) studied 
retrospectively 514 patients in an attempt to determine predictors of PONV.  Among their 
patients, 40 % experienced PONV during the first 24 hours after surgery. In their study, the most 
important predictive factors associated with an increased risk of PONV were female gender, 
young patients (15 to 25 years old), nonsmoking status, presence of predisposing factors (i.e., 
prior history of motion sickness and/or PONV, vertigo or migraine headaches), use of volatile 
general anesthetics, maxillary surgery, postoperative pain level in the PACU and the use of 
postoperative analgesic opioid drugs. They also found a directly proportional relationship 
between the number of risk factors and the prevalence of PONV.  Not surprisingly, Kerger and 
colleagues (2007) also found in their study of the 100 German and Turkish patients, that the 
amount of money patients were willing to pay to prevent PONV, was also related to female 
gender, history of motion sickness and non-smoking status.  
1.4.3 Smoking Advantage 
Among these studies, smoking has consistently been identified as a protectant of PONV.  There 
are two explanations offered in the literature to support these findings. There is a general sense 
that patients who smoke initially have to develop a tolerance to nausea if they continue to smoke 
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(Pomerleau, Pomerleau, Mehringer, Snedecor, Ninowski, & Sen, 2005).  So smokers, used to the 
smoke from cigarettes, are able to exhibit cross tolerance behaviors to other noxious stimuli.  
The second enzymes explanation is chronic exposure to cigarette smoke produces changes in the 
liver microsomal that metabolize nicotine (Sweeney, 2002).   Specifically, there are two enzymes 
in the P450 family that are affected by cigarette smoke; CYP1A2 and CYP2E1.  Tar, the 
condensate of cigarette smoke, is a mixture of polycyclic aromatic hydrocarbons (PAH’s). There 
is some thought that PAHs have a positive effect on the hepatic enzymes, increasing their 
efficiency.   Both CYP1A2 and CYP2E1 are involved in the metabolism of drugs used for 
anesthesia, especially CYP2E1 which is responsible for the metabolism of volatile anesthetics, 
considered one of the major causes of early PONV (Sweeney, 2003).  More efficient enzymes 
are able to more quickly metabolize the anesthetics, decreasing risk of PONV.   Smokeless 
tobacco has also been shown to have a protective effect on PONV.  In a study of 355 
postoperative patients, Brattwall and colleagues (2009) found that smoking or snuffing had an 
equal influence on PONV, which was decreased by 50% in the tobacco group when compared to 
the nonsmokers and “non snuffers”.   The use of the nicotine patch has been suggested as a 
strategy to prevent PONV (Ionescu, Badescu, & Acalovschi, 2007), and is currently the focus of 
an NIH funded study.  
Given that despite the best research, identification of new medications and risk factors, 
20% of postoperative patients still experience PONV, the next logical direction is to explore if 
there are genetic components that could help predict who will experience PONV.    
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1.4.4 CYP450 Genotypes and PONV  
CYP2D6 is located on chromosome 22q1 where it forms part of the CYP2D6 gene cluster with 
two non-functional pseudo-genes, CYP2D7P and CYP2D8P (Arneth, Shams, Hiemke, & 
Hartter, 2009).  CYP2D6, which localizes primarily to the liver, is now believed to be involved 
in the metabolism of 25% of the common drugs administered today, including many opioids and 
anti-emetics (Owen, Sangkuhl, Klein, & Atman, 2009; Zhou, S., 2009).    CYP2D6 was first 
known to effect drug metabolism in a pharmacokinetic study of the antiarrhythmic drug, 
sparteine.  Researchers observed serendipitously that some subjects experienced symptoms of 
nausea and diplopia, which are indicative of toxic doses of Group 1 antiarrhythmics.  They went 
on to report that between 5-10% of Caucasians had a defect in their ability to metabolize this 
drug (Eichelbaum, Spannbrucker, Steincke, & Dengler, 1979).  It is now known that the 
defective metabolism they observed is inherited as an automsomal recessive trait (Sweeney, 
2003).  CYP2D6 is believed to be involved with up to 25% of commonly used medications 
(Owen, Sangkuhl, Klein, & Atman, 2009).  Among the CYP 450 family, CYP2D6 is the only 
noninducible enzyme, which results in a large contribution of genetic variation to the 
interindividual variation noted in enzyme activity (Ingelman-Sundbert, Sim, Gomez, & 
Rodriguez-Antona, 2007).  CYP2D6 is highly polymorphic, with over 90 known allelic variants 
identified (Daly, Brockmöller, Broly, Eichelbaum, Evans, & Gonzalez, 1996).  Some alleles led 
to a complete loss of CYP2D6 function, other allelic variants resulted in hyperfunction.  
Knowing the number of functional gene copies of CYP2D6 per genome has become an 
important determinant of drug clearance for many substrates of this enzyme, in addition to 
genotyping for nonfunctional and variant alleles (Schaeffeler, Schwab, Eichelbaum, & Zanger, 
2003).  
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 Based on the identification of alleles, a system was developed that assigned patients into 
four classifications: poor metabolizers (PM), intermediate metabolizers (IM), extensive 
metabolizers (EM), and ultrarapid metabolizers (UM), where the extensive metabolizers are 
considered to be normal (Ho & Gan, 2006).   In a study that compared the results of 76 liver 
biopsies, average microsomal CYP2D6 protein and enzymatic activity of the four classifications, 
IM and EM were found to be significantly different.   The immunologically quantified CYP2D6 
for the UM group was 23.8 + 7.7 pmol/mg as compared to 2.64 + 2.67 pmol/mg in the IM group 
(p<.01).   Genotype distribution (n=76) was 5% UM, 78% EM, 9% IM and 6% PM (Zanger et 
al., 2001). This distribution is consistent with other studies (Candiotti et al., 2005).   
The polymorphisms identified in the CYP2D6 gene are very different across ethnic groups.  
CYP2D6*10, an allele that leads to decreased functioning, is the most common allele (Zhou, Q. 
et al., 2009), and in fact CYP2D6*10 occurs in almost 50% of Chinese.  CYP2D6*4 is the most 
common allelic variant in Caucasians occurring in 20-24% of the population (Arneth et al., 
2009), yet in Chinese populations is found in only one out of 100 individuals.  CYP2D6*17 is an 
allele that occurs frequently in the Afro-American population causing decreased CYP2D6 
activity. 
   The clinical impact of the CYP2D6 enzyme can be significant.  Patients who were 
classified UM experienced more vomiting compared with the EM or PM groups in subjects 
treated for chemotherapy induced nausea and vomiting (Kaiser et al., 2002).   The same study 
found that patients with CYP2D6*1 allele duplications had lower 5-HT3 drug concentrations.   
In another study that compared 250 patients in terms of their metabolic status, the highest 
percentage of subjects with nausea and vomiting was in the UM group (Candiotti et al.., 2005).  
In their study, when activity was analyzed by genotype, the incidence of PONV in  poor, 
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intermediate, extensive and ultra rapid metabolizers  was 1/12 (8%), 5/30 (17%), 26/176 (15%) 
and 5/11(45%), respectively. The UMs vs all other groups combined resulted in a significant 
difference (p<.01).    Janicki and colleagues (2006) compared treatment of PONV with 
granisetron and dolasetron in relation to the CYP2D6 genotype in 150 subjects considered to 
have moderate to high risk for PONV.  Granisetron is not metabolized by CYP2D6, but a less 
polymorphic CYP3A4, so it not surprisingly that they found those subjects treated with 
granisetron had a more frequent complete response.   Among the subjects treated with 
dolasetron, the greatest incidence of nausea and vomiting was in the subjects who were 
phenotyped as ultra metabolizers.  
1.4.5 Mu-opioid receptor gene  
Opioid receptors belong to the G-protein coupled transmembrane protein class and are present in 
both the central and peripheral nervous systems (Piestrzeniewicz, Fichna, & Janecka, 2006).  
Multiple opioid receptors have been identified (µ, δ, κ) and though they have similarities in 
structure, each has distinct clinical effects and tissue distribution.   In the case of the opioid class 
of drugs, OPRM1 (the µ-opioid receptor gene) has been identified as having the greatest 
relevance in determining a patient’s relative risk of experiencing adverse effects from opioids 
and is most related to analgesia (Reynolds, Ramey-Hartung, & Jortani, 2008).  Several naturally 
occurring single nucleotide polymorphisms (SNPs) have been identified in the µ−opioid receptor 
gene located at chromosome 6q24-25; they are rs1799971 (A118G) and rs1799972 (C17T) 
(Bond et al., 1998).    All of these single nucleotide polymorphisms (SNPs) are non-synonymous, 
resulting in amino acid differences.  The A118G polymorphism results in an asparagine being 
replaced by an aspartic acid. The C17T polymorphism results in an alanine being replaced by a 
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valine.  Therefore differences in genotype are reflected in the protein structure, potentially 
influencing the binding of opioids to these receptors.  In previous work done by Bond and 
colleagues (1998) µ-opioid receptor binding with endorphins was found to be 3 times greater in 
patients with the A118G polymorphism, although there was no difference in binding of 
exogenous opioids.  Bond’s work has not been confirmed and there is some evidence that the 
polymorphism A118G changes the functional properties of the µ-opioid receptor (Kroslak et al., 
2007) but the precise mechanism of the allelic effect is still considered a mystery (Beyer, Koch, 
Schroder, Helmut, & Hoiit,  2004). The µ-opioid SNP that has been studied most frequently is 
the A118G.  Several studies have reported the association of the µ-opioid receptor gene 
polymorphism (A118G) with variations in morphine consumption for analgesia after total knee 
arthroplasty and after total abdominal hysterectomy (Chou, Yang, Lu, & et al., 2006; Chou, 
Wang, Liu, Liu, Tseng, & Jawan, 2006).  Chou and colleagues (2006) in both studies did not find 
statistical differences in the incidence of PONV, but in both studies report a higher incidence of 
PONV in patients who have the AA (wild-type) genotype. That trend was confirmed by the work 
of Sia and colleagues (2008). In their study of women post cesarean-section, they report that 
genetic variation at A118G of the µ-opioid receptor is associated with individual differences in 
pain score, amount of self-administered morphine and the incidence of postoperative nausea. 
Specifically, they found that those subjects who carried the AA (wild-type) for A118G had 
significantly more PONV, despite a lower consumption of PCA morphine postoperatively.  They 
speculated that the greater sensitivity to morphine attributed to the AA (wild-type) genotype 
might also be the reason for the increased PONV (Sia et al., 2008).    
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1.4.6 Pain and PONV   
Chia and colleagues followed over 600 women undergoing gynecological surgery to determine if 
those subjects who experienced postoperative pain also had increased incidence of emesis 
postoperatively. They reported that patients who experienced postoperative emesis had 
significantly higher pain scores (p<.05). They also found, that for those subjects still 
experiencing PONV three days postoperatively, pain was the main risk factor (Chia et al., 2002). 
Patients often describe the very uncomfortable feeling of nausea as being worse than pain, so it is 
important to understand if this uncomfortable feeling may increase the perception of pain.  Pain 
clinical nurse specialists have many anecdotal observations that patients who experience PONV 
also report higher levels of pain; however, the evidence that supports these observations is very 
limited.  
1.4.7 Innovation and Significance 
 Further research is needed to better understand the genetic component of PONV so this negative 
side effect of postoperative opioids can be treated more effectively, if not eliminated all together.  
This exploratory study should lead to future research that would address the interactions between 
multiple genetic variants and also be the framework from which other populations of surgical 
patients can be studied.  It is interesting that the medical literature focuses on assessment of 
PONV in the immediate postoperative period, up to 24 hours postoperatively.  The American 
Society of PeriAnesthesia Nursing (ASPAN, 2006) describes the problems associated with 
PDNV (post discharge nausea and vomiting – which is PONV that occurs after the patient has 
been discharged from the hospital setting), yet there is little research in the literature that 
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describes what happens after the first 24 hours postoperatively.  Few studies have followed 
patients for 48 hours postoperatively, and doing so will provide an increased understanding of 
the potential problem of post discharge nausea and vomiting.   
1.5 RESEARCH DESIGN AND METHODS 
1.5.1 Design 
This study was designed to explore the association between candidate gene genotypes (OPRM1 
and CYP2D6) and PONV in patients undergoing surgery for orthopedic trauma for a single 
extremity fracture.   A secondary analysis was conducted using data from a larger, parent study; 
“The Association between µ-receptor Genotypes and Postoperative Pain Response.”  The 
primary study, under the direction of Richard A. Henker, RN, PhD, was supported by two grants: 
1) AANA Foundation, and 2) Clinical Translational Science Institute grant funded by NIH, 
NCRR 1 UL1 RR024153 and also funded by a Special Grant from the Office of the Senior Vice 
Chancellor for the Health Sciences, University of Pittsburgh.    The parent project is a 
descriptive, prospective study designed to explore the association of µ-opioid receptor genotypes 
and postoperative pain.  In the proposed secondary analysis, an exploratory, prospective design 
was proposed, with two additional variables collected retrospectively from chart audit.   
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1.5.2 Clinical Setting 
The setting for this study was the University of Pittsburgh Medical Center (UPMC) Presbyterian 
Hospital, an 816 bed hospital designated as a Level I Regional Trauma Center fully accredited by 
the Pennsylvania Trauma Systems Foundation.  UPMC-Presbyterian has 43 operating rooms and 
2 post anesthesia care units.  Approval was obtained to conduct the secondary analysis from the 
Principal Investigator and the Co-Investigators of the parent study, and IRB modification 
approval was obtained to collect additional data both retrospectively and prospectively.  
1.5.3 Sample 
Subjects for this study were recruited for the parent study from the UPMC – Presbyterian 
preoperative holding area and medical/surgical units.  UPMC-Presbyterian schedules a minimum 
of 2-5 orthopedic procedures per day, 5 days a week, by orthopedic surgeons.  Inclusion criteria 
for the parent study were patients who were at least 18 years and no more than 70 years old, 
received general anesthesia or general and regional anesthesia for surgery planned to be no more 
than 4 hours, had an isolated orthopedic injury and an American Society of Anesthesiologists 
(ASA) physical status of I, II or III.   The physiology, experience and treatment of pain are 
different in children < 18; therefore, 18 years was selected as starting age for study inclusion.  
Due to the effect age has on patients’ response to opioids; the age of 70 was used for the upper 
limit for age criteria.  Surgical time of greater than four hours has shown to be associated with 
postoperative complications that might have confounded the measure of pain and PONV.  Using 
4 hours of surgical time or less as inclusion criteria controlled for this potential confounder.  An 
isolated fracture and an ASA score < III provided a single cause of pain.  An ASA score greater 
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than III signifies an extremely acute situation that requires surgery within 24 hours for survival.  
Multiple trauma patients were excluded because they have more than one source of pain.  
Exclusion criteria are from the parent study and included treatment with opioids during 
the six months prior to surgery, alcohol use in the 24 hours preceding surgery; recreational drug 
use in the preceding 6 months; and any documented history of alcohol abuse, mental illness, 
hepatic disease, renal disease or neurologic conditions such as stroke, head injury, spinal cord 
injury or intracerebral hemorrhage or previous history of arthritis or bone disease.  Any of these 
situations would be potential competing explanations for the association of opioids and 
postoperative pain and sedation, the focus of the parent study.  There were no additional 
inclusion or exclusion criteria for this study when compared to the parent study.  
1.5.4 Recruitment 
Subjects were recruited as part of the parent study being conducted at the University of 
Pittsburgh, School of Nursing.  Study personnel reviewed the operating room schedules each 
morning to determine if orthopedic procedures were planned. Potential patients with a single 
extremity fracture were reviewed for study eligibility.  Patients were then approached by one of 
the investigators in the preoperative holding area based on the Institutional Review Board 
accepted protocol of the parent study (Appendix A).   If patients agreed to participate verbally, 
informed consent was obtained.   
23 
1.5.5 Research Setting 
All genetic analysis occurred at the University of Pittsburgh, School of Nursing, under the 
direction of Dr. Yvette Conley.  The School of Nursing has a 3200 square foot molecular 
genetics laboratory located in the Victoria Building.  It is divided into three sections, a culture 
room facility, a pre-Polymerace Chain Reaction (PCR) room and a post-PCR/equipment room.  
Major equipment available in the laboratory include an AB1377 automated sequencer/genotyper 
with all the necessary computer equipment and software for analysis of data, the WAVER 
Nucleic Acid Fragment Analysis System from Transgenomic to perform denaturing high 
performance liquid chromatography (dHPLC), and ABI7000 for TaqManR real time PCR and 
allele discrimination assays, a Turner Designs Luminometer, various horizontal/vertical 
electrophoresis units and power supplies, several SSCP apparatus, a gel documentation system, 
centrifuges, a spectrophotometer, a cold room for DNA storage, ultra-low freezers, culture room 
equipment and several 96-well thermal cyclers.  Dr. Conley’s laboratory is completely OSHA 
compliant and up to date for all required inspections.  Two technicians with advanced degrees 
are employed full time in the laboratory.   
1.5.6 Procedures for Data Collection 
All demographic data were collected as part of the parent study. Pain and vital signs data were 
collected preoperatively, 15 minutes after the subject had been admitted to the PACU 
postoperatively and again at 45 minutes after admission to the PACU.  Total amount of opioids 
during the OR and in the PACU were recorded. The presence of PONV was measured 
preoperatively and again 45 minutes postoperatively.  Smoking history, history of previous 
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PONV or motion sickness, and total amount of ondansetron for the 48 hours postoperatively 
were new variables for this study, and were obtained retrospectively from the patients’ medical 
records.   
1.5.7 DNA Specimen 
Saliva samples were collected from all subjects following surgery, usually the morning after so 
rehydration could occur.  The saliva samples were collected using the Oragene DNA self 
collection kit from DNA Genotek corporation.   DNA were extracted from the saliva/buffer 
combination utilizing the protocol and reagents for extraction supplied with the Oragene kit.   
 CYP2D6 SNP genotypes rs16497 (CYP2D6*2), rs3572686 (CYP2D6 *3), rs3892097 
(CYP2D6 *4),   rs5030656 (CYP2D6*9), rs1065852 (CYP2D6 *10), rs28371706 
(CYP2D6*17), rs1135840 (CYP2D6 *39) and whole gene deletion (CYP2D6*5) were 
determined using the TaqMan® Allelic Discrimination Assay (Applied Biosystems, Foster City, 
CA).   An allelic discrimination assay is a multiplexed, endpoint assay that detects variants of a 
single nucleic acid sequence (SNP), which means that it includes more than one primer/probe 
pair (multiplexed) and data is collected at the end of the PCR process (endpoint)  (Applied 
Biosystems, 2010).  
Using the extracted and purified DNA, 1 µl of each DNA sample was placed into a 96-
well optical plate. Added to each well was 12.5 µl of reaction mixture (Taqman® Universal PCR 
master mix, SNP genotyping assay and sterile water).   The polymerase chain reaction and 
fluorescence measurements were performed using the Applied Biosystems Prism 7000 Sequence 
Detection System® with cycling conditions as follows: 
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1. Two minutes at 50º C  
2. 10 minutes at 95º C  
3. 15 seconds at 95º C 
4. 1 minute at  60º C 
5. Step three is repeated 40 times – 15 seconds at 95º 
6. Hold at 60ºC 
After processing, the ABI Prism 7000 Sequence Detection System software produced a plotted 
graph of the results with each allele as an axis of the graph.  Individual cluster plots show strong 
fluorescent signals for each allele, with a clear separation between the three clusters that 
discriminate the variant, heterozygous, and homozygous allelic status.  A plot was generated for 
each CYP2D6 allele included in the analysis for this study. 
Quantitative real time-PCR assays were used to determine the CYP2D6 gene copy 
number using the Taqman® copy number assay (Applied Biosystems.)  In this procedure, 
extracted and purified DNA is added to a reaction mix comprised of TaqMan® Universal master 
mix, Taqman® copy number assay, Taqman® copy number reference assay and sterile water.  In 
this procedure it was imperative that the percentage of DNA is exactly the same for all samples 
so the amount of mix was computed for each individual sample. After the plates were prepared 
they are loaded into the real-time PCR instrument with cycling conditions as follows: 
1. Hold at 95º C for 10 minutes 
2. 40 cycles for 15 seconds at 95º C 
3. 40 cycles for 60 seconds at 60º  
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The process used to quantify the real time-PCR results was the comparative threshold method, 
also known as the [delta] [delta] Ct method.  This process involves comparing the Ct values of  
samples of interest with a control or calibrator such as a non-treated sample or RNA from normal 
tissue.  By employing this method, the [delta]Ctsample is the Ct value for any sample normalized to 
the endogenous housekeeping gene and [delta]Ct, reference is the Ct value for the calibrator also 
normalized to the endogenous housekeeping gene.  For the [delta][delta]Ct calculation to be 
valid, the amplification efficiencies of the target and the reference must be approximately equal. 
If the plot of cDNA dilution versus delta Ct is close to zero, it implies that the efficiencies of the 
target and housekeeping genes are very similar (Applied Biosytems Inc., 2010). To determine 
OPRM1 genotypes a more complicated process was completed starting with the design of 
forward and reverse primers to cover the two  SNPS of interest located in exon 1 of the gene; 
rs799971 (C17T) and 199972 (A118G).    A polymerase chain reaction (PCR) was completed 
consisting of three major steps, denaturation, annealing and extension.  Cycling conditions began 
with 10 minutes at 95º C to activate the process using Amplitaq Gold as a thermal stabler, 
followed by 35 cycles of  1 minute at 95º C, 30 seconds at 59º C and 1 minute at 72º C.  When 
this is completed, the amplified DNA can be held indefinitely at 10º C.   To continue the process, 
the PCR product was mixed with a 1% Agarose gel (10µl) plus 10µ of orange dye to verify that 
the samples were amplified and gel electrophoresed,   Before sequencing could begin, the PCR 
product was cleaned using the EXO SAP It® under very specific conditions to remove any 
uncorporated primers and dNTPs (deoxynucleotides triphosphates).    Sequencing is the process 
of determining the exact order of the bases A, T, C and G in a single SNP.   The sequence data 
were collected using the ABI Prism 377 ® data collection software. The data were analyzed 
by GeneScan ® ABI Prism 77 analysis software.    The computerized results print the nucleotide 
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sequence across the top of plotted traces of each base for detection of base substitutions within a 
SNP.   Validity was achieved by checking the sequencing traces for each section several times.   
All DNA are stored in 1X TE buffer at 4°C.  All analysis was performed in the genetics 
laboratory at the University of Pittsburgh, School of Nursing.  
1.5.8 Study Variables 
The primary dependent variable for this study is PONV.  It is defined as presence of post-
operative nausea and post-operative vomiting that has occurred within 48 hours of surgery, and 
was measured by the presence of rescue ondansetron given during that time. Ondansetron was 
the most consistently found evidence that PONV had occurred during retrospective chart 
reviews. PONV was measured as a nominally scaled, binary variable (Yes/No), but the total 
amount of ondansetron given in the 48 hour postoperative time period, a ratio scaled variable 
was also collected.  The total amount did not include the 4mg of ondansetron given in the OR 
before admission to the PACU.  Because all patients that experienced vomiting also experienced 
nausea, PONV was considered one variable for this study.  
CYP2D6 genetic variances and µ-opioid receptor genetics variances are the primary 
independent variables for this study.   After alleles were identified for each subject, assignments 
to the CYP2D6 classifications were completed following the definitions in Table 2.   There were 
no ultrarapid metabolizers in this study sample, so all subjects were classified as poor 
metabolizers (PM), intermediate metabolizers (IM), or extensive metabolizers (EM) based on the 
combination of the alleles.  Subjects with two fully functional alleles were considered EMs, 
subjects with one functional and one non functional or two decreased function alleles was 
considered an IM.  Subjects with two non functional alleles were considered PMs.   
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For the µ-opioid receptor gene, analyzed from same DNA sample, two single nucleotide 
polymorphisms (SNPs) were studied  based on evidence from previous research that suggests the 
alleles in this area are associated with postoperative pain levels (Chou, Yang, et al., 2006).   
A118G and C17T were classified into one of three genotypes.  These genotypes will be 
homozygous for the wild-type, homozygous for the variant, or heterozygous.  A118G,  is a 
substitution that occurs in 10.5 to 18.8% of the population and, C17T, a substitution that occurs 
in 1-10% of the population (Lötsch & Geisslinger, 2005).  Pain is a secondary dependent 
variable for Specific Aim 4. Pain was operationally defined in this study as the level of pain 
reported by the patient using a verbal pain scale consisting of 11 points – with 0 being the 
absence of pain and 10 being the highest level of pain ever experienced.  Subjects were 
instructed to rate their current pain based on this scale, and were not limited to whole numbers 
(for example a subject may say 5.5)   Pain was measured 15 minutes post-operatively and 45 
minutes post-operatively.  The pain scale is a highly ordinal level of measurement and should 
approximate an interval scaled variable allowing for the use of parametric statistics.  
1.5.9 Covariates   
The four patient factors consistently identified in the literature as risk factors related to the 
occurrence of PONV are smoking status, gender, history of PONV and/or motion sickness and 
opioids uses for postoperative pain.  Opioids were included in the study model as an independent 
variable.  Smoking status, history of PONV and gender were treated as covariates in the data 
analysis plan, with the expectation that they would be ruled out as confounders.  Gender, 
smoking status and history of PONV are dichotomous variables that were measured on a nominal 
scale.  Subjects were considered smokers or nonsmokers based on current activity; therefore a 
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former smoker was considered a nonsmoker.  History of PONV was assessed from 
documentation on the Anesthesia Preoperative Assessment note that is completed by the 
anesthesiologist or nurse anesthetist prior to all surgical procedures at the University of 
Pittsburgh Medical Center. 
1.5.10 Data Management  
SPSS (Version 17.01, SPSS, Inc. Chicago, IL.) was used for data management. Form design, 
data entry, and data verification was performed as per the parent study.  Data were entered into 
the database and visually verified by a member of the research team. Erroneous responses 
identified during data verification were checked and corrected.  Once data were fully verified, 
scores were computed, variables and values were labeled, and missing values identified to create 
the data files for analysis.  All data were stored in password protected computers and the locked 
offices of the primary investigator for the parent study.  The new CYP2D6 genotype data and 
new variables collected for the current study were stored in a database within a password 
protected computer with no other personal identifiers. 
1.5.11 Preliminary Data Analysis Plan  
Data analyses were performed using SPSS (Version 17.01, SPSS, Inc. Chicago, IL).  Initially, 
descriptive and exploratory statistical techniques were employed to describe the data, assess for 
underlying statistical assumptions, and identify any anomalies that would invalidate the results 
from the planned analysis.  Extreme effort was made to retrieve missing data. When outliers 
were detected, they were investigated and, if necessary, corrected values were retrieved by 
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further chart review.  Descriptive statistics (frequencies, percentages, means and standard 
deviations) were computed for all variables and summarized for the entire sample based on 
genotypes, risk factors, PONV, pain, total opioids, and ondansetron doses.  
1.5.12 Justification of sample size for each specific aim 
Specific Aim #1 explores the association between CYP2D6 genotypes and PONV.  Because the 
study is a secondary data analysis, the sample size was fixed at 143 patients that had been 
genotyped for the parent study.  Originally, it was determined that a logistic regression of a 
binary response variable on a binary independent variable with a sample size of 150 would 
achieve  80% power at 0.05 significance level with a minimal odds ratio as small as 4.750.  Odds 
ratio values lower than this likely will be clinically meaningful, even if not statistically 
significant. The preferred effect size measure when comparing predictor variables is the odds 
ratio (Bland & Altman, 2000).   The final sample size used for analysis for this question was 112 
Caucasian patients due to the ethnic differences in genetic studies.  With 112 subjects an odds 
ratio of 3.35 is necessary to achieve 78% power.   
Specific Aim #2 was to explore the association between µ−opioid receptor genotypes and 
PONV.  For specific aim # 2, the final sample size for analysis was 82 due to the number of 
subjects with completed genotyping for the µ-opioid receptor gene in the parent study.  An odds 
ratio, as small as 3.35, in this situation will result in only 66% power.  
Specific Aim #3 was to explore the association of CYP2D6 genotypes and the need for 
rescue anti-emetics in the 48 hours postoperatively.  The planned analysis was an analysis of 
variance (ANOVA) or Kruskal Wallis if parametric assumptions were not met.  The proposed 
sample size of 150 achieves 100% power to detect differences among the means versus the 
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alternative of equal means using an f test with a 0.05 significance level.  The final sample size of 
112 achieves a lower but still moderate power of 78% to detect the differences among the means 
versus the alternative of equal means using an F test with a 0.05 significance level. 
Specific Aim #4 was to explore if subjects who experience PONV report a higher level of 
pain.  For this analysis, a t-test was planned, or a Mann Whitney procedure if parametric 
assumptions were not met. The final sample size of 112 (PONV = 56, No PONV = 56) achieved 
only 17%   power to detect a difference of 0.6 with a significant level of 0.05 using a two- sided 
two-sample t-test. 
1.5.13  Data analysis for specific aims 
Specific Aim #1: To explore the association between CYP2D6 genotypes and PONV.   
Frequency counts were used to describe the frequency distribution and percentages of the 
different CYP2D6 classification assignments. Bivariate correlations were computed among all 
predictor variables and covariates to assess for the risk of multicollinearity.  Suspected covariates 
were the known risk factors of smoking, history of PONV and gender.   The association between 
suspected covariates and all independent variables of interest and the dependent variable were 
computed to determine that they were not also confounders.  Unadjusted (crude) odds ratios were 
first computed using univariate logistic regression.  Hierarchical binary logistic regression was 
then used to determine the relationship for a predictive model of PONV, with the known risk 
factors of smoking, history of PONV and gender, included in the first block, CYP2D6 
classifications, age and opioids were added in the second block and the interaction of CYP2D6 
classifications and opioids in the third.    The study model suggests that CYP2D6 could be a 
moderator between the relationship of opioids and PONV so an interaction between total opioids 
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by weight and CYP2D6 classification was investigated.  The Hosmer Lemeshow test was 
employed to evaluate the goodness of fit of the model and the Omnibus test of model coefficients 
(traditional chi-square method) was used to determine the overall significance of the predictors 
in the model.   
Logistic regression has two main uses; it predicts group membership and also can help 
understand the relationship and strengths among categorical variables.  Logistic regression does 
not assume linearity of relationship between the independent and dependent variables.  It does 
not require normally distributed variables and it does not assume homoscedasticity.  
Specific Aim #2: To explore the association between µ−opioid receptor genotypes and 
PONV. The same statistical methods were originally planned for this aim, as planned for 
Specific Aim #1.  However after the descriptive data were reviewed, one group (the homozygous 
variant [GG] of the µ−opioid receptor gene) had only one observation.  The decision was made 
to combine the heterozygous AG group with the homozygous GG group and term it 
polymorphisms so it is a two group comparison rather than three groups.  
 Specific Aim# 3:  To explore the association of CYP2D6 and the need for rescue anti-
emetics in the first 48 hours post-operatively. If the assumption of a normally distributed sample 
from a normally distributed population is met, parametric statistics can be used.  Because of the 
multiple levels of metabolizers, these data were analyzed using analysis of variance (ANOVA).  
The F statistic was used to test the hypothesis that there would be a difference among the group 
means, with a p-value of <.05 considered statistically significant.  If the assumptions for 
parametric evaluation were not met, a Kruskal-Wallis procedure would have been performed to 
determine group differences.  
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 Specific Aim #4: To explore the association of pain and PONV, a two sample t-test was used 
to compare the level of pain in those subjects who experience PONV and those subjects who do 
not.  The t statistic was used to test the hypothesis that the groups had significantly different 
levels of pain with a p-value of <.05 considered statistically significant. If the data were not 
normally distributed, a non parametric procedure, the Mann Whitney U-test would have been 
employed to compare the two groups.  
1.6 LIMITATIONS 
There are several limitations for this study that require discussion.  As a secondary data analysis, 
the sample size was fixed and thus ability to increase effect size was not possible.  Another 
limitation was based on the fact that some data were collected retrospectively. Retrospective 
research suffers from the risk of missing data, mistakes during interpretation of data or incorrect 
documentation.  A prospective study would allow for real time assessment of PONV, and also 
the measure of the magnitude of PONV possibly employing a visual analog scale.  Prospective 
data collection would be stronger than relying on the documentation of rescue anti-emetics for 
the determination of PONV.  Finally, CYP2D6 knowledge has grown exponentially in the past 
five years, with the identification of new alleles.  Though the CYP2D6 alleles that occur most 
frequently were included in this analysis, there are others that have been identified recently that 
may be significant in the study of postoperative nausea and vomiting and may have influenced 
the outcome. 
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1.7 HUMAN SUBJECTS 
1.7.1 Human Subjects Involvement and Characteristics  
IRB Approval was granted for 200 subjects to be recruited for the parent study which continues 
to accrue subjects.  Inclusion criteria for selection were:  1) Male or female, 2) 18-70 years of 
age, and 3) diagnosis of orthopedic injuries of tibia and/or fibula. The exclusion criteria were: 
Second orthopedic trauma site, abdominal or thoracic trauma, history of mental illness (e.g., 
depression, bipolar disorder, schizophrenia), currently taking phenothiazines, history of hepatic 
disease (e.g., history of hepatitis C), history of renal disease, ASA physical status >3, previous 
history or neurologic conditions such as stroke, head injury, spinal cord injury, intracerebral 
hemorrhage and previous history of arthritis or bone disease.   No special classes of subjects 
(e.g., fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals or 
others) who may be considered vulnerable populations were recruited into the parent study. 
1.7.2 Sources of Materials   
Baseline and postoperative data were collected on all subjects from the medical record that 
included demographic and medical variables such as age, gender, race, medical history and 
condition and amount of medications administered.  Pain scores and assessment of nausea and 
vomiting (PONV in the PACU) were collected directly from the patient in the PACU.  All 
biological specimens were labeled with a unique study identification number. The saliva sample 
was collected after the subject’s surgery for genotyping and was delivered to Dr. Conley’s lab for 
DNA extraction.   
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1.7.3 Potential Risks 
 Confidentiality of the genetic and personal health information collected for this study was 
assured in three ways.  First, all subjects were assigned a unique identification number which 
was used to identify data and samples.  Second, data are reported in aggregate form only.  
Finally, all data files are maintained in a locked office in a locked department in the School of 
Nursing.  All records connecting subjects to data are in a separate locked file.  Electronic data are 
stored on password- protected computers. All samples and data collected for this study were used 
exclusively for research purposes. 
1.7.4 Recruitment and Informed Consent 
Recruitment was conducted by approaching subjects either in their hospital room or in the 
preoperative holding area of the PACU prior to surgery.  An explanation of the study details, 
including all risks and benefits were provided, with subjects given an opportunity to ask any 
questions.  Participation comprehension was assessed by asking subjects why they were being 
asked to be part of the study.  After informed consent was obtained, subjects were provided with 
a copy of the signed document. 
1.7.5 Protection against risk 
 The risks to subjects are limited to possible unknown risks related to breach of confidentiality 
related to disclosure of genetic information. Risk to a breach of confidentiality was minimized by 
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entry of all data immediately into a database where the individual data were linked by a study 
number rather than by personal identifiers.   
1.7.6 Potential benefits of the proposed research to subjects and others  
Potential Benefits of the Proposed Research to the subjects and others – Subjects are likely to 
receive no direct benefit from taking part in this study; however, the information obtained from 
their participation may eventually lead to better methods to prevent or treat PONV. 
1.7.7 Importance of the knowledge to be gained 
The importance of the knowledge to be gained is significant.  This study could advance nursing 
research in the areas of PONV and genetics.  The results of this study could help nurses caring 
for postoperative patients, understand the differences in how patients respond to both pain and 
anti-emetic medications, and the importance of having alternative strategies. The knowledge 
gained from this exploratory study will be significant in the development of future protocols for 
the treatment and prevention of PONV. 
1.7.8 Data safety and monitoring plan  
A Data Safety and Monitoring Committee for the parent study is comprised of the principal 
investigators, co-investigators and statistician. The committee meets quarterly to evaluate the 
progress of the research study, including assessments of data quality, timeliness of participant 
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recruitment, accrual and retention of subjects.  The committee assesses external factors that may 
have an impact on the safety of study participants or the ethics of the research. 
1.7.9 Inclusion of women and minorities 
The majority of patients with the medical diagnosis of orthopedic trauma are men. In the parent 
study, there have been 44 females (39%) and 99 males (61%) recruited to participate.  The parent 
study currently has an ethnic mix that includes Caucasians (79%), African Americans (18%), 
Asians (3%) and Native American Indians (2%).  For the parent study, there are no exclusion 
criteria based on race or gender and every attempt is made to recruit all minority patients 
admitted with a single orthopedic fracture. Children between the ages of 18-21 years are 
included in the parent study.  Children less than 18 years are not included. Subjects younger than 
18 years are excluded because there is evidence that the physiology of pain and PONV in 
children is not the same as adults. 
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2.0  SUMMARY OF STUDY 
The study followed the terms of the proposal in all aspects, with three exceptions.  The original 
conceptual framework was revised to better guide the research, and the planned analyses for 
Specific Aims 1 and 2 were altered due to genotype distribution.  Specific Aim #1 and #3 are 
addressed in the data based manuscript found in Section 4.0. It was decided due to the known 
differences in allelic variation among ethnic groups, and due to the small number of non- 
Caucasian subjects in the sample, that only Caucasians would be included in the evaluation of 
these specific aims. That decision resulted in a sample size of 112.  When this sample was 
compared to the larger sample in terms of smoking, gender, history of PONV and age there were 
no significant differences.  Genotyping resulted in no ultrarapid metabolizers (UM) in this group 
of subjects, so data analysis compared EMs to IMs and PMs.  Specific Aims #2 and #4 are 
restated below, followed by results and discussion.   
Specific Aim #2:  To explore the association between µ−opioid receptor genotypes and 
PONV in subjects admitted for orthopedic surgical repair of a single fracture to an extremity.   
Results: A total of 82 subjects were included in this analysis.  The sample was based on 
the number of subjects who were genotyped for µ-opioid receptor gene as part of the parent 
study. There are no patterns in the selection of these subjects, and when compared to the larger 
sample they were similar in terms of gender (69% men) and smoking status (45% smokers).  The 
mean age was also the same (38.9 years) and 47% percent experienced PONV (as compared to 
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50% of the larger sample).    The distribution of the A118G SNP alleles was  as follows:   63 
(77%) subjects were AA (wild-type), 18 (22%) subjects were heterozygous AG, and only 1 
(<1%) subject was GG.  The distribution of the C17T SNP alleles was as follows: 76 (93%) 
subjects were CC (wild-type), 18 (22%) subjects were heterozygous CT, and only 1(<1%) 
subject was TT.  Due to only one subject in the GG and TT groups, the polymorphism groups 
were combined for statistical comparison as shown in Table 3.  Twenty seven subjects (42%) of 
wild type groups experienced PONV as compared to 10 (58%) of the combined polymorphism 
group.  The unadjusted odds ratio and confidence intervals comparing the wild type group with 
the combined polymorphism group were OR = 0.641 (95% CI= 0.261- 1.674), p value = .362.   
Logistic regression, controlling for the known covariates of smoking, history of PONV and 
gender did not reveal a significant interaction between opioids and OPRM1 genotypes as a 
predictor for PONV.   
 
Table 3:  Cross tabulation for OPRM1 genotypes and PONV 
 
   PONV 
Total    NO YES 
 Wild type (AA and CC) n 33 25 58 
%  56.9% 43.1% 100.0% 
    
Polymorphism (CT, TT 
AG or GG) 
n 11 13 24 
%  45.8% 54.2% 100.0% 
    
                             Total n 44 38 82 
%  53.7% 46.3% 100.0% 
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Discussion: A lack of significant findings is not totally surprising, based on the mixed 
results reported in the literature (Chou, Yang et al., 2006, Chou, Wang et al., 2006).   It is 
surprising that the trends, noted by other authors that showed a greater incidence of PONV in the 
AA (wild-type) group could not be confirmed in this study.  A larger sample size may allow for a 
stronger comparison. 
Specific Aim # 4 was to explore if subjects who experience PONV report a higher level 
of pain than those subjects who do not experience PONV.  
Results:  The sample for this comparison was the Caucasian sample of 112 subjects 
described in the first specific aim.  To address this specific aim, first descriptive statistics were 
computed.  The mean pain score at 15 minutes after admission to the PACU for those subjects 
who experienced PONV was 6.54 + 3.23 compared to the mean for subjects who did not 
experience PONV; 7.13 + 2.93.   A t-test for independent groups was computed to compare the 
means.  The results did not show a significant difference (p =.308).  Pain scores at 45 minutes 
post admission to the PACU were also compared.  The mean pain score at 45 minutes after 
admission to the PACU for those subjects who experienced PONV was 5.80 + 2.76 compared to 
the mean for subjects who did not experience PONV; 6.60 + 2.84.    Results are depicted in 
Figure 2.   
Discussion: The genetics of pain and PONV are actually working in opposite directions, 
with subjects that experience PONV reporting less pain than those who do have PONV.  This is 
consistent with the findings noted in the u-opioid receptor gene literature where patients who are 
more sensitive to opioids and require less morphine for pain management have an increased 
incidence of PONV (Sia et al., 2008).  To examine this aim further, a t-test was computed to 
compare the total amount of opioids received by patients with PONV compared to patients who 
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did not experience PONV.   Once again the results were not significant (p =.364).   Though the 
differences were not significant, subjects who experienced PONV required less amounts of 
opioids than those subjects who did not experience PONV.  
 
 
Figure 2:  Comparison of mean pain scores in subjects with and without PONV 
 
Pain level as measured by 11 point verbal pain scale (VPS) in subjects who experienced and did not experience 
postoperative nausea and vomiting.  The VPS score means are not significantly different at either point in time, 
though at both time points those patients who experienced PONV reported lower pain scores. 
 
The results of this study support further research in patients with PONV.  There are still well 
documented gaps in our knowledge of this surgical complication.  All subjects in this study 
received 4 mg of ondansetron before they left the OR, yet 68 (47.5%) patients of the total sample 
of 143 experienced PONV within 48 hours of surgery requiring rescue anti-emetic ondansetron.   
 The strengths of this study can be defined by the differences we see in those subjects who 
experience PONV compared to those subjects who do not experience PONV.  When the 
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CYP2D6 classification groups are compared to incidence of PONV, there was a significant 
difference between the PMs and the EMs, and also a significant interaction between the CYP2D6 
classification and total opioids received. This is the first nursing research project known that has 
examined PONV in terms of CYP2D6 classifications.  The significant results add to the body of 
knowledge that will be helpful as personalized medicine becomes more prominent.  
 There are several limitations to this study that should be addressed, and they are 
consistent with the limitations described in the original proposal.  The inherent problems of 
retrospective research are a severe limitation.  Going back in time to retrieve missing data can be 
very challenging, and the researcher is at the mercy of the nurse or physician who provided the 
original documentation that was scanned into the medical records.  Sometimes it is easy to 
decipher, other times it is very difficult to interpret.  A prospective study will would allow for 
real time assessment of PONV, not relying on rescue medications to define PONV.  Another 
limitation is the sample size of this study, and the lack of UMs in the sample obtained.  The lack 
of UMs prevented this study from the ability to compare UMs with PMs in regards to total 
amount of ondansetron received for PONV.  A larger future study would hopefully be able to 
address that question.  Finally, the increased number of CYP2D6 alleles that have been identified 
in the past several years is also a limitation of the study.  Though the analysis for this study 
compared the most frequently occurring alleles, there are others not identified in this study that 
may have an association with PONV.  
 Future studies are needed in the area of postoperative complications, especially to 
determine genetic risks for PONV.  A stronger prospective study with a larger sample would 
include urine drug levels to compare drug metabolite ratios with CYP2D6 allele assignments.   
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3.0  MANUSCRIPT 1: A REVIEW OF THE GENETICS OF POSTOPERATIVE 
NAUSEA AND VOMITING 
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3.1 ABSTRACT 
Postoperative nausea and vomiting (PONV) is recognized as one of the most common side 
effects of surgery, affecting as many as one third of all surgical patients.  Previous studies have 
successfully established the major patient risk factors   However, despite the best research, 
identification of new medications and risk factors, as many as 30% of postoperative patients still 
experience PONV.  The purpose of this article is to review recent studies that have presented a 
potential genetic association and the incidence of PONV that may further explain this gap.  
3.2 THE NOT SO LITTLE PROBLEM 
Postoperative nausea and vomiting (PONV)  is the most common complication after general 
anesthesia. Despite new medications, and new technology the incidence of PONV continues to 
be 20-30%, thus affecting as many as one third of the over 71 million surgical patients annually 
(ASPEN, 2006).   Potential adverse effects of PONV in addition to causing extreme discomfort 
for the patient can include aspiration, wound dehiscence, bleeding, hematoma, dehydration,  
electrolyte imbalance, delay in ability to begin oral medications, exhaustion and general delay in 
mobilization and recovery (Miaskowski, 2009; Jolley, 2001).  PONV is one of the strongest 
predictors for prolonged hospital stay and unanticipated admission for outpatient surgical 
patients (Pradham, Crichton, Edmonds, 1999) costing what could account for millions of dollars 
of health care costs annually (Apfel, Kranke, & Eberhart, 2004.  Researchers and physicians 
have referred to PONV as the “big little problem,” (Lichtor & Glass, 2008;  Nelson, 2002),  but 
nurses who care for postoperative patients know that PONV is not a little problem, and know 
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that it can be more worrisome than pain.  In fact, when patients are given dollars to 
hypothetically “buy” away potential postoperative complications, vomiting was chosen above 
pain, with nausea also a major concern for patients (Kerger et al., 2007).   
3.2.1 Pathways of PONV    
Understanding the mechanism behind PONV helps one understand the treatment guidelines, and 
also why it can be such a complicated problem.  The use of opioids for postoperative pain is 
recognized as being the primary cause of PONV (Watcha & White, 1992).  Opioids cause PONV 
through three distinct mechanisms; yet all eventually stimulate the emetic center in the medulla 
which triggers nausea and vomiting.  The first mechanism occurs when opioids cause a reduction 
in gastrointestinal motility.  The reduced motility generates a release of serotonin from the 
enterochromaffin cells in the gastrointestinal tract.  Enterochromaffin cells produce 
approximately 90% of the body’s store of serotonin (Nielson & Olsen, 2008).  Serotonin then 
binds to the visceral 5HT3 receptors, stimulating vagal afferent neurons that in turn activate the 
vomiting center via the nucleus tractus solitarius (NTS) which is connected to the area postrema.  
The second mechanism occurs when opioids stimulate the chemoreceptor trigger zone in the 
brainstem, which causes a release of serotonin and dopamine that directly activate the emetic 
center by binding to receptor sites (Gan, 2007; Nielson & Olsen, 2008).   A third mechanism 
develops when opioids enhance the sensitivity of the middle ear to movement.  This action 
activates the emetic center by the release of histamine and acetylcholine from vestibular fibers 
(Jolley, 2001; Silva, O’Ryan, & Poor, 2006).   
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3.2.2  How do we treat PONV?   
Blocking these multiple neurotransmitter receptor sites is the focus of most anti-emetic drugs, 
and many agents have been developed to act against one or more of receptors (Neilson & Olsen, 
2008).   Each of these pathways provides an opportunity to reduce PONV as they each function 
independently.   Though, because of their independence, there is significant empirical evidence 
that supports the use of multiple drugs to prevent or treat PONV.   Guidelines established by an 
expert panel recommends the use of combination therapy with 2 or 3 prophylactic agents from 
difference classes for patients who are considered to be high risk for PONV (Gan et al., 2007).   
Based on the published guidelines for the management of PONV, the first drug of choice 
is a 5HT3 receptor antagonist such as ondansetron.   In higher risk patients the addition of other 
anti-emetics is recommended.  Frequently, dexamethasone, a glucocorticoid, is given to augment 
the effectiveness of the HT3 receptor antagonists.  Other anti-emetics which are used include the 
histamine receptor antagoinist, promethazine; dopamine receptor antagonists, metocloprimide or 
prochlorperazine; and the scopolamine patch which adds anticholinergic properties (Gan et al., 
2007). 
3.2.3 So who is high risk?  
Risk Factors have been identified by multiple researchers studying the ability to predict those 
patients most vulnerable to develop PONV.  The patient risk factors most frequently identified 
include female gender, smoking status, history of PONV or motion sickness and use of opioids 
for postoperative pain (White, O’Hara, Roberson, Wender, & Candiotti, 2008; Apfel et al.,  
2008; Murphy, Hooper, Sullivan, Clifford, & Apfel, 2006).  On the basis of two independent 
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studies, Apfel and colleagues developed a simplified risk score for predicting PONV (Apfel, 
Laara, Koivuranta, Greim, & Roewer, 1999).  In a study of 1,137 subjects, they assigned one 
point for each major identified risk factor, so a non-smoking female with a previous history of 
PONV that was treated with opioids for postoperative pain would be assigned a score of four.  
Apfel and colleagues found that the presence of none, one, two, three or four of these risk factors 
translated to an increased incidence of PONV by 10%, 21%, 39%, 61% and 79% respectively.    
The Risk Factor Assessment Tool has been further tested and provides support for 
physicians and nurses who need to decide upon prophylactic anti-emetic therapy. It seems 
especially valuable for those patients who are considered high risk (Apfel et al., 2008; Weilbach, 
Rahe-Meyer, Weissig, Scheinichen, & Piepenbrock, 2006). Apfel’s work on risk factors 
continues to be validated by further research.  In a recent observational cohort study that 
examined variations in the serotonin receptor genes (HTR3A and HTR3B), 95 subjects with 
PONV were compared to 95 subjects that did not experience PONV in the PACU following 
surgery.   When the demographics of the two groups were compared they found that the PONV 
group had more women (p < .001), less smokers (p= .03) and had a history of PONV (p <.001).  
Both groups were comparable in amount of opioids received postoperatively (Reuffert et al., 
2009).     
Given the evidence, it appears that the successful PONV management strategy should 
include the identification of patients at risk;  keeping the baseline risk low; and when risk is high; 
using a combination of anti-emetics acting on different receptors.  However, anyone who spends 
time in a postoperative acute care unit (PACU) quickly realizes that there are patients not 
considered high risk that develop PONV.  
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3.2.4 Even the best strategies do not always work: A case study 
MC is a 37 year old male who was admitted for an open reduction and internal fixation of his left 
femur.  He had no history of motion sickness or previous PONV and he is a two pack a day 
smoker.  He did receive opioids for pain.  Yet postoperatively, despite having a risk factor score 
of one, and having been medicated with ondansetron an hour before leaving the operating room, 
he was extremely ill with nausea and vomiting in the PACU.  MC was considered to have a 
relatively low risk for PONV, and in fact there is evidence that his smoking status alone 
potentially should have provided protection (Brattwall et al., 2009).   So what made this patient 
so very sick?  Despite the best research, identification of new medications and risk factors, as 
many as 20% of postoperative patients still experience PONV.   
3.2.5 Could there be a genetic link causing this patient to develop PONV?  
The purpose of this review was to explore the established association of the CYP2D6 genotypes 
and the ΟPRM1  genotypes with PONV in adult patients.  CYP2D6 and OPRM1 are the genes of 
focus, because they are the genes that are thought to hold the greatest relevance to determining a 
patient’s relative risk of experiencing PONV following opioid therapy (Reynolds, Ramey-
Hartung, & Jortani, 2008).   However, due to the limited number of studies found in this area, 
studies looking for the association of other candidate genes and PONV were included.  All 
studies reviewed were published between 2002 and 2010.  Inclusion criteria were quantitative 
studies limited to adult patients that measured nausea and vomiting as side effects of treatment, 
most commonly surgery. Key words used were PONV, CYP2D6, OPRMI1, postoperative 
complications, opioids and genetics.  PUBMED, OVID, CINAHL databases were searched using 
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all possible combinations of the key words.   The literature review resulted in 16 studies (Table 
4) from the United States, Sweden, Denmark, Switzerland, France, Germany, Taiwan, Denmark 
and Japan.     
3.2.6  How do differences in CYP2D6 genotypes affect PONV? 
CYP2D6, a member of the CYP450 superfamily, was first shown to effect drug metabolism in a 
pharmacokinetic study of the antiarrhythmic drug, sparteine.  Researchers serendipitously 
observed that some subjects experienced symptoms of nausea and diplopia, which are indicative 
of toxic doses of sparteine.   Thirty years later researchers have demonstrated that the defective 
metabolism first localized by Eichenbaum and colleagues (1979) is inherited as an autosomal 
recessive trait affecting the CYP2D6 gene (Sweeney, 2003). It is now recognized that the 
enzyme defect begins from a mutation leading to a faulty expression of the enzyme.  CYP2D6 is 
highly polymorphic, with over 100 known allelic variants identified, and more are discovered 
every year.  Based on CYP2D6 genotyping, patients are assigned into one of four classifications: 
poor metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (EM) and 
ultrarapid metabolizers (UM) (Table 2).   Patients that fall in the UM group have a gene copy 
number variant, and possess at least three functional wild-type alleles which cause a too rapid 
drug metabolism.   Extensive metabolizers are considered to be normal and have the expected 
response to medications (Ho & Gan, 2006).  The IM group may experience some or lesser degree 
of drug response, and the PM group will have an extremely slow or no drug metabolism. PM 
status is caused by a faulty expression of the enzyme with either complete deletion of CYP2D6 
or more commonly, a replacement of a single nucleotide leading to aberrant gene splicing 
(Gaedigk, Blum, Gaedigk, Eichelbaum, Meyer, 1991).  In the case of pro-drugs, that require 
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CYP2D6   for conversion to active drug status, PMs may not respond at all (Ingelman-Sundberg, 
Oscarson, McLellan, 1999).    
Several studies focused on subjects who were classified as UM believing those patients 
would be at greater risk for developing PONV.   Candiotti and colleagues (2005) compared 250 
female patients in terms of their CYP2D6 metabolic status and incidence of PONV.   When the 
88 subjects who experienced PONV were analyzed by genotype, 45% (5 out of 11 patients) who 
were classified as UM experienced PONV; compared to 8% who were PMs, 17% who were IMs, 
and 15% in the EM group.   Janicki and colleagues (2006) compared treatment of PONV with 
granisetron and dolasetron in relation to the CYP2D6 genotype in 150 subjects considered to 
have moderate to high risk for PONV.  Granisetron is not metabolized by CYP2D6, but a less 
polymorphic CYP3A4, so it would be expected that those subjects treated with granisetron had a 
more frequent complete response.   Among the subjects treated with dolasetron (a drug that is 
metabolized by CYP2D6) the greatest incidence of nausea and vomiting occurred in subjects 
who were classified as UM.   Kirchheiner, Jan-Tobias, Bauer, Roots, & Brockmöller (2008), 
studied the response to opioids in healthy subjects who were predetermined to have either the 
UM or EM classification.  Patients classified as UM were more sensitive to opioids than those 
who are classified as EM.    In a different population of patients, Kaiser and colleagues (2009) 
also found significantly more nausea and vomiting in their oncology patients who were defined 
as UMs.  They studied 270 patients receiving their first day of chemotherapy to compare the 
relationship between CYP2D6 genotypes and effectiveness of anti-emetic treatment.   Nausea 
and vomiting were assessed within the first 4 hours and then 5-24 hours after treatment.   Patients 
with 3 active CYP2D6 genes (classified UMs) demonstrated the highest incidence of vomiting 
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and nausea after chemotherapy and the lowest serum concentrations of tropisetron from blood 
drawn the same day (Kaiser et al., 2002).  
The current anti-emetic drug of choice is ondansetron; a serotonin receptor antagonist 
that is metabolized by CYP2D6, so it is not surprising that several of the research articles 
reviewed focused on the metabolism of ondansetron, or the association of CYP2D6 genotypes on 
the effectiveness of ondansetron.   Stamer, Rauers, Eun-Hae, Mubhoff, & Stüber (2009) found 
that surgical subjects that possessed three or greater active CYP2D6 alleles (and were thus 
classified as UM) had reduced ondansetron plasma concentration compared to those subjects that 
had zero to two active alleles.  Candiotti and colleagues (2005) also observed a higher incidence 
of ondansetron failure for vomiting in their subjects with three or more copies of the CYP2D6 
gene.   There is strong evidence that those subjects who are genotyped as UMs will experience 
rapid drug metabolism and be at an increase risk for PONV, though based on the population, as 
few as 2% of patients will be categorized as UMs ( Zhou, S., 2009).  
Other researchers have looked more closely at the larger number of patients classified as 
IM or PM.  Zwisler and colleagues (2009) compared only PMs and EMs in their study of hypo- 
analgesic effects of oxycodone in 33 healthy volunteers.   They found statistical differences in 
the analgesic effects of oxycodone but they did not find differences in the opioid side effects of 
nausea and vomiting. In a study from Korea, Kang and colleagues looked only at CYP2D6 allele 
10 (CYP2D6*10) in 135 women hospitalized for gynecologic surgery.  CYP2D6*10 (common in 
Asian populations) would result in classification of IM.   All patients were treated with 4 mg of 
ondansetron before extubation.  The study results showed no statistical differences in the 
incidence of PONV in patients who were wild-type, heterozygous or homozygous for 
CYP2D6*10 (Kang et al., 2006).    
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A published case study about a CYP2D6 poor metabolizer demonstrates the potential of 
personalized medicine.  The report describes an 85 year old woman recovering from hip surgery.  
The patient had a long standing intolerance to codeine, and during her first admission was 
ordered oxycodone combined with tramadol. The initial oxycodone dose was 5mg combined 
with 500 mg of acetaminophen every 12 hours.  The dosage was increased to 10 mg every 12 
hours and then 7.5 mg every 6 hours.  Analgesia was still not achieved, and the patient suffered 
severe nausea and vomiting.  The patient was discharged on famotidine for the persistent PONV.   
A year later the same patient was readmitted for further hip surgery.  Prior to surgery she was 
genotyped for CYP2D6 classification and was found to be a poor metabolizer.  Knowing this, the 
physicians report that they effectively adjusted postoperative medications so that pain relief was 
obtained, without the very uncomfortable side effects of PONV (Susce, Murray-Carmichael, & 
de Leon, 2006).   
3.2.7 OPRM1 and PONV  
The µ-opioid receptor gene single nucleotide polymorphism (SNP) that has been studied most 
frequently in terms of opioid response is A118G.  Several studies have reported the association 
of the µ-opioid receptor gene (A118G) with variations in morphine consumption for analgesia 
after total knee arthroplasty and after total abdominal hysterectomy (Chou, Yang, et al., 2006; 
Chou, Wang, et al., 2006). In both studies, Chou and colleagues did not find statistical 
differences in the incidence of PONV, but in both studies report a higher incidence of PONV in 
patients who have the homozygous (AA) variation.  The strong trend reported was based on 
observing 22% of subjects in the AA group with PONV, as compared to 12% and 7% in the 
heterozygous (AG) and homozygous variant (GG) groups respectively.  This trend was 
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confirmed by the work of Sia et al., (2008).  In their study of women post cesarean-section, they 
report that genetic variation at A118G of the µ-opioid receptor is associated with individual 
differences in pain score, amount of self administered morphine and the incidence of 
postoperative nausea. Specifically results showed that those subjects who carried the AA (wild-
type) for A118G had significantly (p =.02) more PONV, despite a lower consumption of PCA 
morphine postoperatively.  Sia and colleagues believe that a greater sensitivity to morphine may 
be attributed to the AA allele and thus lead to the increased PONV that was observed in the wild-
type group.   
3.2.8 Other candidate genes that influence the occurrence of PONV? 
Several articles focusing on other candidate genes and PONV were identified in recent literature. 
Coulbault and colleagues (2006) investigated the genetic factors on morphine dose requirements 
and adverse events after colorectal surgery in a pilot study of 74 patients.  The study compared 
the association of µ-opioid receptor gene (SNP A118G), the gene UGT2B7 (SNP T802C), the 
gene ABCB1, and gene MDR1 (G2677T/A & C3435T) with patient characteristics.  Morphine 
side effects were measured in this study by the use of ondansetron for PONV.    Study results 
revealed only one borderline (p=.07) predictive factor, which was the ABCB1 GG-CC diplotype.  
Another study that examined the association of the ABCB1 and µ-opioid genes and adverse 
opioid drug reactions focused on oxycodone.  In this study, Zwisler and colleagues (2009) 
recruited 33 healthy volunteers who were exposed to experimental pain.   In this small sample, 
there were no significant differences between the genotypes for the µ-opioid A118G, however 
they observed a significant difference (p=.02) in adverse reactions (nausea and vomiting) 
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between the ABCB1 C3435T wild-type group when compared to patients possessing the variant 
alleles. 
Two additional articles were reviewed that address the association of genetics with 
PONV.  Reuffert and colleagues (2009) studied the variations in the 5-HT3A and 5-HT3B 
serotonin receptor genes to see if they influence the occurrence of postoperative vomiting. 
Comparing 95 postoperative patients that experienced PONV with 94 control patients, they 
observed significantly higher risk (p=.003) in those patients who were carriers for the HTR3A 
variant c1377A>G.   The study results revealed several HTR3B variants that were associated with 
a lower risk for PONV, though these significant genetic variants were located in the noncoding 
regions of the gene (Reuffert et al., 2009).  The final article reviewed studied the relationship 
between Dopamine D2 receptor TaqIA polymorphisms and PONV.  Nakagawa and colleagues 
(2008) enrolled 1070 subjects who were scheduled for elective surgery under general anesthesia.  
They found that the relative risk for the A2A2 allele in comparison to the A1A1 or A1A2 was a 
significant risk factor for the development of early onset PONV.  Understanding the multiple 
pathways that can lead to PONV, both studies provide support for additional research.   
3.2.9 Discussion 
Many of the studies reviewed have moderate sample sizes with several extremely large (Sia et 
al., 2008 and Nakagawa et al., 2008).  Of the 16 studies reviewed, eleven used postoperative 
patients for their populations.  One study looked at patients beginning their course of 
chemotherapy; one study used patients from a Pain Clinic and the other three recruited healthy 
volunteers.   
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In the studies that sought an association between CYP2D6 and PONV results are mixed 
depending upon the metabolic classification examined.  Results observed from the studies that 
focused on the ultra metabolizers report strong evidence that patients classified as UM are at 
greater risk for developing PONV (Candiotti et al., 2005; Janicki et al., 2006; Kirchheiner et al., 
2008).  Though as Kaiser noted, at least fifty patients would have to be genotyped to protect one 
patient from severe emesis (Kaiser et al., 2002).   In the study that explored the association of 
CYP2D6 EMs and PMs with PONV, no significant differences were found, though the sample as 
noted above was relatively small and they were healthy volunteers, not surgical patients 
(Zwisler, et al., 2009).   The case study (Susce, et al., 2006) provides a good example of why 
PMs may have as much risk as those subjects who are UMs.  If drugs are used that must be 
metabolized by CYP2D6, patients will have no response instead of a rapid response causing 
PONV to persist.   Kang and colleagues (2006) looked only for CYP2D6*10, an allelic variant 
that is found more frequently in the Asian population (Zhou, S. 2009).  CYP2D6*10 is known to 
cause reduced metabolic activity and patients with this allele are considered to be IMs.  
Ondansetron was given to all subjects (all women) prior to leaving the OR, yet there was no 
variability in PONV when genotypes were compared.  
The articles reviewed that studied the µ-opioid receptor gene (A118G)  consistently 
reported a higher incidence of PONV in the A118G AA (wild-type) groups as compared to those 
patients who were AG or GG.   Though only one study found statistical significance (Sia, A., et 
al., 2008),   Chou and colleagues (2006) found in their patients recovering from knee surgery and 
abdominal hysterectomy, that patients, who were in the wild-type group experienced more 
PONV despite the fact that they required less morphine.  Patients who are AA could be more 
57 
sensitive to opioids, requiring lower doses for pain relief, yet due to a more intense response 
have increased PONV.  
 Lötcsh and colleagues (2009) recruited their subjects from patients who were followed at 
a Pain Center, so their sample included both patients with chronic and acute pain, in fact the 
average time on pain therapy was over five years.  Perhaps they did not find significant 
differences in opioid side effects because these chronic pain patients have developed a tolerance 
to the noxious opioid response that leads to PONV.  Patients who are sensitive to opioids would 
also request alternative pain medication, so the sample could be in some ways self selected.  
Both scenarios might explain the low occurrence of nausea and vomiting (2.9%) overall noted in 
this paper (Lötcsh et al., 2009).  
The articles that addressed the association of PONV and dopamine receptor and serotonin 
receptor genes (Rueffert et al., 2009 & Nakagawa et al., 2008) are not strong enough to stand 
alone.  However, due to the multiple pathways that lead to PONV, they provide evidence that the 
influence of these genes should be investigated in additional studies with appropriate sample 
sizes.  
3.2.10 Summary 
The candidate genes that have been considered as suitable targets for the study of PONV based 
on articles published in the past 8 years were the aim of this review.   The results of all studies 
provide sufficient evidence for further research in this area, even with inconsistent and some-
times contradictory findings.
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Table 4: Studies included in literature review 
 
Author, Year, Title 
 
Sample 
Description 
 
Study Design 
 
Study 
Intervention/Analysis 
 
     Study 
Findings/Outcomes  
 
Candiotti, K. A.et al. 
(2005). The impact of 
pharmacogenomics 
on postoperative  
nausea and vomiting: 
do CYP2D6 allele 
copy number and 
polymorphisms affect 
the success or failure 
of ondansetron 
prophylaxis?  
 
 
 
250 female 
patients  
 
Prospective 
observational 
study 
 
All subjects pre-
medicated with 
Ondansetron 30 
minutes before 
intubation.  PONV 
assessed  at       
 
The incidence of 
vomiting in UM 
subjects (5/11 or 
45.5%) was 
significantly 
increased as 
compared to the PM 
(8.3%), IM (16.7%) 
or EM (14.7%) 
groups.  Patients 
with 3 normally 
functioning 
CYP2D6 alleles 
might benefit from 
administration of 
anti-emetics not 
metabolized by 
CYP2D6. 
 
 
 
Janicki, P., et al., 
(2006).  Prevention of 
Postoperative Nausea 
and Vomiting with 
Granisetron and 
Dolasetron in 
Relation to CYP2D6 
Genotype.   
 
 
 
150 adults 
 
 
Randomized 
Double Blind 
Study  
 
 
 
Compared 
effectiveness of two 5-
HT3 antagonists 
(Granisetron and 
Dolasetron) in 
relations to CYP2D6 
genotype. Granisetron 
is metabolized 
independently of 
CYP2D6.  
 
Findings suggest 
that the difference 
in the anti-emetic 
response may be 
associated with 
differences in the 
carrier status for 
duplication of the 
CYP2D6 allele, 
with subjects in the 
UM classification 
experiencing more 
vomiting episodes. 
The Granisetron 
group required less 
rescue medication 
as compared to the 
Dolasetron group.  
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Kirchheiner, J. et al. 
(2008). Effects of the 
CYP2D6 Duplication 
on the 
Pharmacokinetics and 
Pharmacodynamics 
of Tramadol.  
 
 
11 subjects 
who were 
classified as 
UM, 11 
subjects 
classified as 
EM, 
Healthy male 
volunteers, 
18-65 years.  
 
 
Observational, 
cohort study  
 
 
Comparison of results 
of cold pressure test, 
pupillometry and 
standardized adverse 
event recording in 
subjects who were 
UM vs EM. 
 
 
5/11 (45%) of the 
UM group 
experienced nausea 
after tramadol 
compared to 1/11 
(9%) in the EM 
group.   
 
Stamer, U., et al. 
(2009).   Ondansetron 
for the treatment of 
opioid induced 
nausea and vomiting: 
Impact of 
Cytochrome 
Polymorphisms.  
 
 
 
92 adults 
scheduled for 
abdominal 
surgery  
 
Prospective, 
observational 
study 
 
Comparison of 
metabolism of 
Ondansetron and 
association of 
CYP2D6 alleles. 
Carriers of >3 active 
CYP2D6 showed 
reduced plasma 
concentrations of 
ondansetron 
compared to carriers 
of <2 active alleles.  
Increasing the 
dosage of 
ondansetron from 
4mg to 8mg did not 
significantly 
increase the 
ondansetron plasma 
concentration.  
 
Kaiser, R., et al. 
(2002). Patient-
tailored anti-emetic 
treatment with 5HT3 
receptor antagonists 
according to 
cytochrome P-450 
2D6 genotypes.   
 
 
 
270 cancer 
patients 
receiving their 
first day of 
chemotherapy.  
 
Prospective, 
observational 
study 
 
Comparison of anti-
emetic activity of   
ondansetron or 
tropisetron as related 
to functional 
polymorphisms of e 
CYP2D6. Nausea and 
vomiting were 
assessed within the 
first 4 hours and then 
5-24 hours after first 
chemotherapy 
treatment.   
 
 
 
 
 
 
Patients with 3 
active CYP2D6 
genes (UMs) 
demonstrated the 
highest incidence of 
vomiting and nausea 
after chemotherapy 
when ondansetron 
or tropisetron was 
given.   
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Susce, M., et al. 
(2006). Response to 
hydrocodone, codeine 
and oxycodone in a 
CYP2D6 poor 
metabolizer.  A case 
study.  
 
 
 
 
85 year old 
female (n=1) 
 
 
 
Case Study  
  
 
 
Severe history of 
PONV not 
controlled with anti-
emetics. Following 
hip surgery, 
rehabilitation was 
complicated by 
continued multiple 
episodes of nausea 
and vomiting.  
CYP2D6 
genotyping resulted 
in poor metabolizer 
classification.  
 
Zwisler, S. et al. 
(2009). The 
hypoanalgesic effect 
of oxycodone in 
human experimental 
pain models in 
relation to the 
CYP2D6 oxidation 
polymorphism. 
33 healthy 
volunteers 
aged 22-32 
years 
genotyped 
either 
CYP2D6 EM 
or PM.    
Randomized, 
placebo 
controlled, 
double 
blinded 
crossover 
design with 
washout 
Pain tests were 
performed 1, 2, 3 and 
4 hours after 
medication.  Side 
effects were observed 
by self report using a 4 
point verbal rating 
scale.  
There were no 
differences in 
number of subjects 
in each group who 
experience nausea 
or in the average 
nausea score (2.5 in 
the PM group vs 2.9 
in the EM group). 
No treatment for 
nausea was offered. 
 
Chou, W. et al. 
(2006). Human 
opioid receptor 
A118G 
polymorphism affects 
intravenous patient-
controlled analgesia 
morphine 
consumption after 
total abdominal 
hysterectomy. 
 
 
 
 
 
 
80 female 
patients 
admitted for 
total 
abdominal 
hysterectomy. 
 
Prospective, 
observational 
study 
 
Subjects were 
genotyped for A118G 
polymorphism at the 
µ− opioid receptor 
gene. Morphine (via 
PCA) consumption, 
pain and side effects 
were measured for 48 
hours following 
surgery. 
 
 
 
 
 
The incidence of 
PONV was higher 
in patients of the 
AA and AG group 
than the GG group, 
though the 
differences were not 
statistically 
different.  7 (16%0 
of the AA group 
were observed to 
experience vomiting 
as compared to 6% 
in the GG group 
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. 
 
Sia, A, et al. (2008). 
A118G single 
nucleotide 
polymorphism of 
human mu-opioid 
receptor gene 
influences pain 
perception and 
patient-controlled 
intravenous morphine 
consumption after 
intrathecal morphine 
for post cesarean 
analgesia.  
 
588 healthy 
women who 
received 
intrathecal 
morphine for 
post cesarean 
analgesia. 
 
Prospective, 
observational 
study 
 
 
 
 
 
All subjects were 
genotyped for the 
A118G 
polymorphism. Pain 
scores, PONV, and 
total morphine were 
measured for the first 
24 hours. 
 
Subjects who were 
wild type (AA) for 
the A118G 
polymorphism 
reported the lowest 
pain scores.  The 
same group had the 
highest incidence of 
postoperative 
nausea versus the 
AG and GG groups 
(p<.02) 
 
            Chou, W., et al. 
(2006).  Association 
of µ-opioid receptor 
gene polymorphism 
(AI18G0 with 
variations in 
morphine 
consumption for 
analgesia after total 
knee arthroplasty.   
 
 
147 patients 
admitted for 
total knee 
arthroplasty 
 
Prospective, 
observational 
study  
 
Subjects were 
genotyped for A118G 
polymorphism at the 
µ− opioid receptor 
gene. Morphine (via 
PCA) consumption, 
pain and side effects 
were measured for 
hours following 
surgery. 
 
 
Though there were 
no significant 
differences found 
among the groups 
for PONV, the wild 
type (AA) group 
had a higher 
incidence as 
compared to the 
allelic variant 
groups.  
Coulbault, L., et al. 
(2006). 
Environmental and 
genetic factors 
associated with 
morphine response in 
the postoperative 
period. 
 
 
 
 
 
 
 
 
 74 
postoperative 
colorectal 
surgical 
patients 
Descriptive, 
prospective 
pilot study  
The purpose of the 
study was to 
determine the 
association of 
OPRM1, UGT2B7 
and ABCB1 with total 
morphine given in 24 
hour period and 
PONV requiring 
ondansetron.  
This study found 
that neither 
UGT2B7 nor 
OPRM1 genetic 
polymorphism 
could be identified 
as predictive factors 
for the need for 
curative 
ondansetron, though 
23% of subjects 
who were AA for 
A118G experienced 
PONV also  
compared to 8% and 
1% of subjects who 
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were heterozygous 
or homozygous 
variant. Subjects 
with the ABCB1 
homozygous wild 
type diplotype 
required 
significantly less ( 
p=.028) anti-
emetics as 
compared  
Zwisler, S., et al. 
(2009).  
The antinociceptive 
effect and adverse 
drug reactions of 
oxycodone in human 
experimental pain in 
relation to genetic 
variations in the 
OPRM1 and 
ABCB1genes. 
33 healthy 
volunteers 
aged 22-32 
years 
Randomized, 
placebo 
controlled, 
double 
blinded 
crossover 
design with 
washout 
Pain tests were 
performed 1, 2, 3 and 
4 hours after 
medication.  Adverse 
drug reactions were 
measured by self 
report using a 4 point 
verbal rating scale. 
There was not a 
significant 
difference between 
wild-type and 
variant allele groups 
for the OPRM1, 
A118G 
polymorphism.  
There was however 
a significant 
difference in the 
ABCB1 G2677T. 
Nausea and 
vomiting was 
significantly 
different for the 
volunteers with the 
wild-type genotype 
as compared to 
carriers of the 
variant allele 
(p<.0005) 
 
Lötsch, J., et al. 
(2009). Cross-
sectional analysis of 
the influence of 
currently known 
pharmacogenetic 
modulators on opioid 
therapy in outpatient 
pain centers.  
 
352 subjects 
treated with 
opioids for 
pain of 
various 
origins. 
 
Cross-
sectional, 
descriptive 
study  
 
The purpose of this 
study was to describe 
associations of genetic 
variants with opioid 
dose, pain score and 
side effects.  
 
 
 
No significant 
genetic associations 
with opioid side 
effects were 
identified, though 
subjects with more 
side effects had 
higher opioid daily 
doses.  Only 2.8% 
of subjects 
experienced nausea 
or vomiting.  
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Nakagawa, M. 
(2008). Dopamine D2 
receptor Taq IA 
polymorphism is 
associated with 
postoperative nausea 
and vomiting.  
 
 
1070 patients 
scheduled for 
elective 
surgery. 
 
 
Descriptive, 
observational 
study.  
 
 
Patients were assessed 
for vomiting and/or 
need of rescue anti-
emetics within 6 hours 
(early PONV) and 
within 24 hours (total 
PONV) of surgery. 
 
 
 
 
 
Early PONV was 
observed in 11.3% 
and total PONV in 
14.9% of subjects.  
The relative risk 
associated with the 
A2A2 allele in 
comparison with 
A1A1 or A1A2 
alleles was 1.27 
(95% CI, 0.88-1.84) 
for total PONV.  
Reuffert, H. et al. 
(2009). Do variations 
in the 5-HT3A and 5-
HT3B serotonin 
receptor genes 
(HTR3A and 
HRT3B) influence 
the occurrence of 
postoperative 
vomiting? 
95 patients 
with history of 
POV and 94 
normal 
controls. 
Non-
interventional 
cohort design 
 
Correlation of 
identified genetic 
variants with 
postoperative 
vomiting by logistic 
regression then 
compared to normal 
controls. 
The HTR3A variant 
c1377A>G was 
associated with a 
significantly higher 
risk (OR=2.97. 95% 
CI=1.46-6.02) for 
PONV.  
 
Kang, J. et  al. 
(2006). Influence of 
5-HT3b Receptor 
AAG Deletion 
Mutation and 
CYP2D6 *10 on 
Ondansetron 
Treatment. 
 
135 women 
gynecological 
surgery  
 
Descriptive 
study  
 
All patients were 
medicated with 
Ondansetron 15 
minutes prior to 
extubation.   
 
Study results found 
the incidence of 
PONV were not 
different among the 
genotypes of 
CYP2D6*10 and 
5HT3b AAG.  
CYP2D6  
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4.0  MANUSCRIPT 2: THE ASSOCIATION OF CYP2D6 GENOTYPES AND 
POSTOPERATIVE NAUSEA AND VOMITING IN CAUCASIAN TRAUMA PATIENTS 
ADMITTED FOR SINGLE EXTREMITY FRACTURES 
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4.1 INTRODUCTION 
Postoperative nausea and vomiting (PONV) has long been a concern for nurses caring for 
surgical patients.  It is one of the strongest predictors for prolonged hospital stay and 
unanticipated admission for outpatient surgical patients (Pradham, Crichton, Edmonds, 1999) 
costing what could account for millions of dollars of health care costs annually (Apfel, Kranke, 
& Eberhart, 2004).   Potential adverse effects of PONV in addition to causing extreme 
discomfort for the patient can include aspiration, wound dehiscence, bleeding, hematoma, 
dehydration, electrolyte imbalance, delay in ability to begin oral medications, exhaustion and 
general delay in mobilization and recovery (Miaskowski, 2009; Jolley, 2001).   
4.2 BACKGROUND 
Postoperative nausea and vomiting, well known, but not totally explained, is the most common 
complication for postoperative patients (Apfel et al., 2004).  Research on PONV is primarily 
divided into two major focuses; identification of risk factors and studies evaluating the best 
treatment options.  Yet despite the evaluation of new medications and risk protocols, 20-30% of 
postoperative patients continue to experience PONV (Kranke, Roewer, Smith, Piper, 
Wallenborn, & Eberhart, 2009).   Based on the multiple pathways that can lead to PONV some 
researchers have focused on the use of combinations of anti-emetic medications (Gan, 2007; 
Golembiewski, Chernin, & Chopra, 2005).  In high risk patients, combining two or more anti-
emetics with different mechanisms of action has been shown to be more effective than using a 
single agent. These new combination strategies have improved the management of PONV but by 
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no means have they eliminated the problem (Ho & Gan, 2006).  Other research has focused on 
identification of risk factors in order to predict those patients who are most likely to experience 
PONV (Apfel et al.,  2008; White, O’Hara, Robertson, Wender, & Candiotti, 2008;  Murphy, 
Hooper, Sullivan, Clifford, & Apfel, 2006).  In a recent paper addressing the gaps in knowledge 
regarding the treatment of nausea and vomiting, the authors noted that although there have been 
important advances in the last twenty years, one of the major and most interesting gaps is the 
relatively poor ability to treat nausea (Sanger & Andrews, 2006).  
4.2.1 Major Risk Factors of PONV  
The patient risk factors most frequently identified by previous studies include gender, smoking 
status, history of PONV or motion sickness and use of opioids for postoperative pain (White et 
al., 2008; Apfel et al., 2008; Murphy et al., 2006).   On the basis of two independent studies, 
Apfel and colleagues developed a simplified risk score (PONV Risk Factor Assessment Tool) for 
predicting PONV (Apfel, Laara, Koivuranta, Greim, & Roewer, 1999).  In a study of 1,137 
subjects, they assigned one point for each risk factor known, so a non-smoking female with a 
previous history of PONV that was treated with opioids for postoperative pain would be assigned 
a score of four.  They found that the presence of none, one, two, three or four of these risk factors 
increased the incidence of PONV by 10%, 21%, 39%, 61% and 79%, respectively.   The Risk 
Factor Assessment Tool has been further tested and continues to successfully give physicians 
and nurses the opportunity to provide guidance for prophylactic anti-emetic therapy, especially 
focusing on those patients who are considered high risk (Apfel et al., 2008).   
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4.2.2 CYP450 Genotypes and PONV  
CYP2D6 is located on chromosome 22, where it forms part of the CYP2D6 gene cluster with 
two non-functional pseudo-genes, CYP2D7P and CYP2D8P (Arneth, Shams, Hiemke, & 
Hartter, 2009).  CYP2D6, which localizes primarily to the liver is now believed to be involved in 
the metabolism of 25% of the common drugs administered today, including many opioids and 
anti-emetics (Owen, Sangkuhl, Klein, & Atman, 2009; Zhou, S., 2009).    CYP2D6 was first 
known to affect drug metabolism in a pharmacokinetic study of the antiarrhythmic drug, 
sparteine.  Researchers serendipitously observed that some subjects experienced symptoms of 
nausea and diplopia, which are indicative of toxic doses of Group 1 antiarrhythmics.  They 
reported that between 5-10% of Caucasians had a defect in their ability to metabolize this drug 
(Eichelbaum, Spannbrucker, Steincke, & Dengler, 1979).  It is now known that the defective 
metabolism they observed is inherited as an automsomal recessive trait (Sweeney, 2003).  
CYP2D6 is highly polymorphic, with over 150 known allelic variants and subvariants identified 
(Ingelman-Sundberg, Daly, & Nebert, 2009).  Some alleles lead to a complete loss of CYP2D6 
function, others lead to reduced activity.  Based on allelic variants, a system has been developed 
to assign patients into four CYP2D6 classifications (Table 5). The classifications are: poor 
metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (EM) and ultrarapid 
metabolizers (UM).  The extensive metabolizers are considered to be normal (Ho & Gan, 2006).   
Saschse and colleagues report the prevalence of the different metabolizers within the Caucasian 
population as:  PMs 5-10 %, EMs 70-80%, IMs 10-17% and UMs 2-5% (Sachse, Brockmöller, 
& Bauer, 1997).    Due to potential overlap and clinical similarities of the IM and EM groups, 
they are sometimes reported as one group labeled EM/IM (de Leon, Armstrong, Cozza, 2006; 
Arneth, Shams, Hiemke, & Hartter, 2009). 
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Table 5: Definitions for the four CYP2D6 classifications 
  
The clinical impact of the CYP2D6 enzyme can be significant.  Patients who were 
classified UM experienced more vomiting compared with the EM or PM groups in subjects 
treated for chemotherapy induced nausea and vomiting (Kaiser et al., 2002).   The same study 
found that patients with CYP2D6 wild-type allele duplications had lower 5-HT3 drug 
concentrations.   In another study that compared 250 patients in terms of their metabolic status, 
the highest percentage of subjects with nausea and vomiting was in the UM group (Candiotti et 
al., 2005).  In their study, when activity was analyzed by genotype, the incidence of PONV in  
poor, intermediate, extensive and ultra rapid metabolizers  was 1/12(8%), 5/30 (17%), 26/176 
(15%) and 5/11(45%), respectively.  When the UMs were compared to all other groups, a 
significant difference (p<.01) was noted.    UMs will clear the body of CYP2D6 substrates more 
quickly than the other groups, and consequently are at risk for sub-therapeutic plasma levels (de 
Groot, Wakenhut, Whitlock, & Hyland, 2009).   
 The most common variant alleles found in the Caucasian population are CYP2D6*4 
(23%) which causes a splicing defect resulting in a non functioning allele, and CYP2D6*5 (4%), 
that results in the total deletion of CYP2D6 (Johansson, Lundqvist, Dahl, & Ingelman-Sundberg, 
Classification Abbreviation Definition 
Ultrarapid Metabolizer UM Possessing at least three fully functional alleles 
Extensive Metabolizer EM At least one fully functional CYP2D6 allele 
Intermediate Metabolizer IM Two reduced functional alleles, or one non 
functional allele 
Poor Metabolizer PM Two non functioning alleles – no enzyme activity 
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1996; Arneth et al., 2009).  Patients who are homozygous for CYP2D6*5 and CYP2D6*4 are 
classified as PMs.  PMs are actually at risk for two potential types of problems.   First, because 
they metabolize CYP2D6 substrates (drugs that require CYP2D6 to be metabolized) more 
slowly, they have increased plasma exposure to those drugs, which may increase the risk for a 
drug induced adverse reaction.  PMs are also at risk for reduced efficacy from a medication that 
requires CYP2D6 for conversion to an active drug.   Oxycodone, for example, a medication used 
frequently for postoperative pain requires CYP2D6 for the creation of oxymorphone, the active 
metabolite of oxycodone (Holmquist, 2009).  Combining the understanding of the known risk 
factors for PONV and the potential genetic association is very important in the quest to decrease 
or eliminate this very common and distressing postoperative complication.  The primary purpose 
of this study was to explore if there was an association between the PONV and the CYP2D6 
genotypes, and if there was an interaction effect between CYP2D6 classification and amount of 
opioids given in regard to PONV.   
4.3 METHODS 
4.3.1 Design and Sample 
With Institutional Review Board approval, secondary analysis was conducted using data from a 
larger study; “The Association between Mu-receptor Genotypes and Postoperative Pain 
Response”. The primary study, under the direction of Richard A. Henker, RN, PhD, was 
supported by two grants: 1)AANA Foundation, and 2) Clinical Translational Science Institute 
grant funded by NIH, NCRR 1 UL1 RR024153 and also funded by a Special Grant from the 
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Office of the Senior Vice Chancellor for the Health Sciences, University of Pittsburgh.  In this 
secondary analysis, a descriptive study design was employed, with two additional variables 
collected retrospectively by the author from chart audit.  The subjects for the primary study were 
recruited from an 816 bed tertiary hospital that is a certified Level One Trauma Center.  Subjects 
were recruited in the preoperative holding area on the day of the surgical procedure, if they 
agreed to be take part in the study, informed consent was obtained.   
Inclusion criteria for the parent study were subjects who were at least 18 and no more 
than 70 years old, received general anesthesia or general and regional anesthesia for surgery 
planned to be no more than 4 hours, had an isolated orthopedic injury and an American Society 
of Anesthesiologists (ASA) physical status of I, II or III.   The physiology, experience and 
treatment of pain are different in children and in the elderly; therefore 18 and 70 years were 
selected as starting and ending ages for study inclusion.  Surgical time of greater than four hours 
has shown to be associated with postoperative complications that might have confounded the 
measure of pain and PONV.  Using 4 hours of surgical time or less as inclusion criteria 
controlled for this potential confounder.  An isolated fracture and an ASA score < III provided a 
single cause of pain.  An ASA score greater than III signifies an extremely acute situation that 
requires surgery within 24 hours for survival.  Multiple trauma patients have more than one 
source of pain.  
Because there are known differences in CYP2D6 alleles based on ethnic differences, and 
a limited number of non-Caucasians, only Caucasians were included in this study. Other 
exclusion criteria are from the parent study and included treatment with opioids during the six 
months prior to surgery, alcohol use in the 24 hours preceding surgery, recreational drug use in 
the preceding 6 months, any documented history of alcohol abuse, mental illness, hepatic 
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disease, renal disease or neurologic conditions such as stroke, head injury, spinal cord injury or 
intracerebral hemorrhage or previous history of arthritis or bone disease.  Any of these situations 
would be potential competing explanations for the association of opioids and postoperative pain 
and sedation; the focus of the parent study.  
4.3.2 Measures 
Demographic and Patient Characteristics 
Information on demographic characteristics, current smoking status, history of previous PONV, 
total amount of ondansetron, and total amount of opioids administered was obtained from the 
patient’s hospital chart.  Pain was assessed via self report 15 minutes after the subject had been 
admitted to the post anesthesia care unit (PACU) postoperatively and again at 45 minutes after 
being in the PACU.   Pain was operationally defined on an 11 point verbal pain score (VPS).   
Patients were instructed to describe their pain from 0 to 10, with 0 representing no pain and 10 
representing the worst pain ever imagined.   Data for PONV were collected as binary variables, if 
the patient reported nausea, or was observed vomiting or if they were given postoperative 
ondansetron, they were considered to be positive for PONV.   PONV was measured at two 
points, PONV that was observed or reported in the PACU and total PONV that occurred with 48 
hours of surgery as measured by the need for rescue doses of onadansetron.  The total amount of 
opioids that were administered during the procedure and in the PACU was recorded.  All 
administered opioids were converted to morphine equivalence (Table 1) for comparison 
(McCaffery & Pasero, 1999), and then adjusted by weight for the score used in this study. 
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 Genetic data  
A saliva sample was collected from all subjects following surgery usually the following morning 
after surgery so that rehydration could occur.  The saliva samples were collected using the 
Oragene DNA self collection kit from DNA Genotek corporation.   DNA was extracted from the 
saliva/buffer combination utilizing the protocol and reagents for extraction supplied with the 
Oragene kit.  Using the prepared DNA, CYP2D6 genotypes were determined by the TaqMan 
Allelic Discrimination Assay (Applied Biosystems, Foster City, CA) using the ABI Prism 7000 
sequence detection system.  Quantitative real time-PCR assays were used to determine the 
presence of multiple CYP2D6 gene copy numbers.  The Allelic Discrimination Assay included 
rs16497 that defines allele CYP2D6*2, rs3572686 (CYP2D6 *3), rs3892097 (CYP2D6 *4), 
  rs5030656 (CYP2D6*9), rs1065852 (CYP2D6*10), rs28371706 (CYP2D6*17), rs1135840 
(CYP2D6 *39) and CYP2D6*5 which is defined by whole gene deletion (Table 2). Based on 
genotyping results, subjects were classified as EMs, IMs, or PMs as defined in Table 3.  Subjects 
who had two fully functional alleles were defined as EMs.  Subjects with one fully functional 
allele and one decreased function or a non functioning allele were assigned IM status.  Subjects 
with two nonfunctioning alleles were defined as PMs.  All DNA are stored in 1X TE buffer at 
4°C.  All analyses were performed in the genetics laboratory at the University of Pittsburgh, 
School of Nursing.   
4.3.3 Data Analysis 
Statistical analyses were carried out using SPSS 17.0 (SPSS, 2009). Descriptive statistics were 
computed for each variable. Correlations were computed for all predictor variables to assess for 
the risk of multicollinearity.  The association between suspected covariates and all independent 
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variables of interest and the dependent variable was computed to determine that they were not 
also confounders.   Suspected covariates were the known risk factors of smoking, history of 
PONV and gender. All patients were administered opioids during surgery or in the PACU so 
opioids were not considered a covariate in this study.  Unadjusted odds ratios were computed 
using univariate logistic regression. 
 Hierarchical binary logistic regression was used to determine the relationship for PONV 
with the CYP2D6 classifications controlling for the known risk factors of smoking, history of 
PONV and gender by their inclusion in the first block.   The study model suggests that CYP2D6 
could be a moderator between the relationship of opioids and PONV so an interaction between 
total opioids by weight and CYP2D6 classification was investigated.  The Hosmer Lemeshow 
test was employed to evaluate the goodness of fit of the model.  The Omnibus test of model 
coefficients (model chi-square) was used to determine significance.  ANOVA was used to 
compare the means of the three CYP2D6 classifications for amounts of ondansetron given in 48 
hours and total amount of opioids administered. The level of significance was set at p < 0.05 for 
two sided hypothesis testing. 
4.4 RESULTS  
One hundred and twelve Caucasian patients who underwent surgical repair for a single isolated 
extremity fracture met the inclusion criteria. Demographic data are summarized in Table 7. 
There were more men (n= 81 72%) and non smokers (n=66, 59%).  The average age was 39 
years, and 24 (21%) of subjects reported a positive history of PONV.  The incidence of PONV in 
the PACU was 38% but increased to 50% during the first 48 hours after surgery.  The average 15 
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minute postoperative pain scores were 6.83+ 3.08, and 6.20 + 2.82, 45 minutes after admission to 
the PACU.    
 The distribution of subjects according to CYP2D6 classification was as follows: there 
were 7 (6%) subjects who were classified into the PM group, 34 (30%) were IMs and 71(63%) 
were EMs. No UMs were identified from this sample. The most frequently occurring allele was 
CYP2D6*2 with 86 alleles followed by CYP2D6*1 with 75 alleles.  Thirty-two (34%) subjects 
had at least one CYP2D6*4 allele, with 6 (5%) subjects being homozygous *4/*4 (Table 6).  One 
subject had two decreased functioning alleles (*9/*9) and based on phenotype was assigned PM 
status.  
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Table 6:  Demographic data and patient characteristics (n=112) 
    Variable           n (%) or Mean + SD 
Female Sex        31 (28%) 
Non Smoker        66 (59%) 
History of PONV      24 (21%) 
PONV in the PACU       38 (34%) 
PONV in 48 hours after surgery     56 (50%) 
CYP2D6 – Extensive Metabolizer     71 (63%) 
CYP2D6 – Intensive Metabolizer     34 (30%) 
CYP2D6 – Poor Metabolizer      7 (6.3%) 
Total Opioids+ (mgs)            0.49 + 0.26 
Total Ondansetron *(mgs)    3.39 + 4.26 
PACU Pain Score at 15 minutes    6.83 + 3.08  
PACU Pain Score at 45 minutes   6.20 + 2.82 
Age in years                  39.1 + 12.7 
 
*Does not include ondansetron given in the operating room  
+adjusted by weight 
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         Table 7:  Classification assignments based on allele combinations 
 
Allele Combination 
 
Number (Percent of sample) 
 
Classification Assignment 
*1*1 15(13.5%) Extensive Metabolizer (EM) 
*1/*2 5(4.5%) Extensive Metabolizer (EM) 
*2/*2 18(16%) Extensive Metabolizer (EM) 
*2/*39 25(22.3%) Extensive Metabolizer (EM) 
*39/*39 2(1.8%) Extensive Metabolizer (EM) 
*1/*3 1(0.9%) Intermediate Metabolizer (IM) 
*1/9 3(2.7%) Intermediate Metabolizer (IM) 
*1/*10 4(3.6%) Intermediate Metabolizer (IM) 
*1/*4 32(28.5%) Intermediate Metabolizer (IM) 
*9/*9+ 1(0.9%) Poor Metabolizer (PM) 
*4/*4 6(5.3%) Poor Metabolizer (PM) 
 
Unadjusted (crude) odds ratios derived from univariate analysis are displayed in Table 7.  
Female gender and history of PONV were significant risk factors in this study, smoking was not 
a significant factor. Multivariate logistic regression results are displayed in Table 8.  The 
omnibus test of model coefficient X2, for this model, was 31.839 (p< .000).  The Hosmer and 
Lemesow goodness of fit test, for this model, was Χ² =13.261 (p =.130).   Using the EM group as 
the reference, logistic regression analysis revealed a trend toward a significant difference with 
the CYP2D6 PM group for presence of PONV (p =.085), but did not find significance 
differences for the CYP2D6 IM group.  A significant interaction between total opioids adjusted 
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by weight and CYP2D6 PMs (p=.010) was observed but significant interactions between total 
opioids and the other two CYP2D6 classifications were not found to be present.   The significant 
interaction of opioids and CYP2D6 PM in regards to PONV represented the observation that 
those subjects classified as PM, who received higher doses of opioids were less likely to 
experience PONV 
Figure 3 depicts a comparison of the means of total ondansetron and total opioids 
adjusted by weight, across the three CYP2D6 classifications. Using an ANOVA procedure there 
was a significant difference in the amount of total opioids received across groups (p=.007). 
Results of an ANOVA procedure did not reveal a significant difference in the amount of 
ondansetron across the same groups (p =.270). However as shown on Figure 3, the PM group 
received 2.28 + 3.15 mgs of ondansetron compared to 3.88 + 4.38 mgs of ondansetron in the EM 
group.  The range of total ondansetron for the PM group was from 0 mgs to 8 mgs, the range for 
the EM group was 0 – 20 mg of Ondansetron.  
4.5 DISCUSSION  
Distribution of CYP2D6 classification groups for this study, are consistent with previous studies.  
The PM group was 6.7 %, falling between the 5-10% usually reported in other studies (Owen et 
al., 2009; Zhou, S., 2009).  The small percentage of UMs typically found in a sample of 112 
could yield as low as a group of two, so it is not that unusual a UM was not identified from this 
sample.   The IMs and EMs, if combined, describe 93% of the sample.  However, for this study, 
an attempt was made to differentiate between the EMs and IMs, with evidence that there may be 
detectable differences between the groups.  The mean total opioids adjusted by weight was 
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significantly different across the three groups, with a modest “intermediate” step between the 
EM and PM groups, providing some confidence that there was an intermediate group.   A recent 
study examined serum levels of patients who were treated with the antidepressant venlafaxine.  
They found that serum ratio levels of venlafaxine to ODV (major metabolite from venlafaxine 
produced by CYP2D6) for patients with one CYP2D6*4 allele were found to be higher than 
those patients with two *4 alleles, yet significantly less than subjects who were EMs, thus they 
labeled them IMs (Arneth et al., 2009).  The *4 allele is present in high frequency and accounts 
for >75% of allelic variants in Caucasians (Stamer, Bayerer, Wolf, Hoeft, & Stuber, 2002).  
Stamer’s findings are consistent with the results of this study, in which CYP2D6*4 was the 
mutant allele detected most frequently (n=38).  The two other variant alleles detected were 
CYP2D6*9 (n=4) and CYP2D6*3 (n=2).  The one subject with two decreased functioning alleles 
(*9/*9) by definition should probably be considered an IM (Owen et al., 22009) but based on 
phenotype was assigned PM status.  This subject required the highest amount of postoperative 
opioids of all subjects and reported pain levels of 10 both 15 minutes and 45 minutes 
postoperatively.    
Even with the small number of subjects in the PM group, the significant findings from 
logistic regression between the EM and PM group for PONV, and the significant interaction of 
the PM group by total opioids given are noteworthy.  PMs in this study were less likely to 
experience PONV as compared to the EM group, yet received higher doses of total opioids 
adjusted by weight. Most researchers have reported no significant differences in incidence of 
PONV between EMs and PMs (Janicki et al., 2006; Candiotti et al., 2005) though Susce and 
colleagues (2006) described a PM who had a very poor postoperative response to both anti-
emetics and opioids in a published case report.   
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Gaedigk and colleagues (2008) have developed a CYP2D6 activity score (AS) in an 
attempt to simplify genotype interpretation. Using their AS system, an allele that has no 
metabolic activity is assigned a zero score, an allele that has decreased function is assigned a half 
of a point (0.5), a normal allele receives one point, and two points are assigned when multiple 
gene copies are present.  Using the AS, CYP2D6*1/*4 would be assigned a score of 1.0.  This 
provided a higher level of discrimination, and they were able to detect small differences between 
the EM and IM classifications that they confirmed with urinary metabolite data (Gaedigk, 
Simon, Pearce, Bradford, Kennedy, & Leeder, 2008).  
In our study, fifty percent (56) patients were treated with ondansetron during the PACU 
and during the 48 hours post surgery compared to 38(34%) of patients who reported PONV in 
the PACU alone. This is consistent with many studies focused on postoperative complications 
(Meng & Quinlan, 2006; Janicki et al., 2006).  It is standard practice in our institution to 
medicate all surgical patients with 4mg of IV ondansetron prior to leaving the operating room 
(OR).  The dose given in the OR was not included in the amount of ondansetron recorded as part 
of the study, yet even with the administration of this prophylactic dose of ondansetron in the OR, 
34% of our subjects experienced PONV in the PACU.  
 The American Society of PeriAnesthesia Nursing (ASPAN, 2006) describes the 
problems associated with PDNV (post discharge nausea and vomiting), yet there is little research 
in the literature that describe what happens after the first 24 hours postoperatively. This study 
demonstrated that patients with PONV increased from 34% to 50% during the 48 hours after 
discharged from the PACU. This is significant when the number of same day surgical procedures 
is considered, making discharge teaching in regards to PONV of critical importance. 
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When the three CYP2D6 classifications were compared, the PMs Mean ondansetron was 
less than 2.5 mgs for the 48 hours postoperative period, with no one in this group requiring more 
than 2 doses of ondansetron (ondansetron is given in 4mg doses usually every six hours).  The 
range was broader for the IM and EM group in this respect, with patients in both groups 
requiring up to 20 mg of ondansetron in the 48 hours postoperatively.  The results for total 
opioids are paradoxical compared to the ondansetron.  Those patients who required the most 
opioids had the least PONV, and those subjects who required the most anti-emetics had the 
lowest amount of opioids for pain (Figure 1).   There was a significant difference for PONV in 
the CYP2D6 PM group when compared to the EM group.    
There was not a significant difference in verbal pain scores across the three groups.  This 
may be explained by the subjective nature of pain.  Nurses taking care of postoperative patients 
appropriately accept the patient’s subjective report of pain whether the score is 6 or 10, assessing 
more for changes in their score rather than the reported score.  Verbal pain scores are stronger 
measures of intra-patient variability than inter-patient variability, and validation for verbal pain 
scores are reported in terms of the ability to measure individual pain scores (Cork, Isaac, 
Elsharydah, Saleemi, Zavisca, & Alexander, 2004).    
 It is not surprising that two of the major risk factors for PONV,  a positive  history of 
PONV and gender were significant predictors of PONV in this study, they are both well 
documented from previous research (Apfel et al., 2008)  What is surprising, is that smoking, 
usually a strong predictor was not found to have a significant influence.  This may be due to the 
increased number of smokers in the sample.  The American Heart Association (2008) reports that 
18-21 percent of Americans are current smokers, compared to the 43% current smokers found in 
this group of orthopedic trauma patients.  Brattwall and colleagues reported that 32% of subjects 
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in their study were current smokers or snuff users.  They reported that PONV was reduced by 
50% in both genders on the day of surgery and the first postoperative day in the 
smoking/snuffing group (Brattwall, Stomberg, Rawa, Segerdahl, Houltz, & Jakobsson, 2009). 
Interestingly, they reported that smoking or snuffing equally reduced PONV.    
  Though not included as one of the four major risks in most adult PONV scoring systems 
(Apfel et al., 1999)  age has been identified in other studies as a moderate predictor for PONV 
(Sinclair, Chung, Mezei, G., 2000; Junger, Hartmann, Genson, 2001). The relatively young age 
of this adult sample (39 years) might contribute to the strong influence of age in this study.    
Two factors described in the literature as possible predictors for PONV were controlled for by 
study inclusion criteria.  They are type of surgery and length of surgery (Sinclair et al., 2000; 
Junger et al., 2001).  All study participants were admitted for an orthopedic procedure for single 
isolated extremity fracture and all subjects with surgery time greater than 4 hours were not 
included.   
4.5.1 Limitations of the study 
This study primarily was based upon secondary data analysis; however several new variables 
were added through retrospective data collection. Retrospective research suffers from the risk of 
missing data, mistakes during interpretation of data or incorrect documentation.  In the future, a 
prospective, controlled research study that follows patients postoperatively and measures PONV 
directly is needed to confirm these findings.  Another limitation was the sample size.  A larger 
sample not only would provide more power to the study, but would also allow for a stronger 
comparison if large enough to identify patients that fall into the UM classification.   
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4.5.2 Conclusion and implications clinical practice 
Ultimately personalized medicine will allow health care providers to treat all patients 
individually.   To prepare for that eventuality, it is necessary for clinical genetic research to 
continue to identify those risks that may lead to a negative outcome.  Sweeney (2003) noted that 
health care providers should consider inter–individual variability in response to medications a 
major clinical problem.  The ability for nurses to recognize those patients who are not responding 
from treatment and know when to implement appropriate alternative strategies is imperative for 
successful postoperative recovery.  Nurses, who recognize that patients may respond differently 
to medications due to genetic variants, will be more understanding when a postoperative patient 
requires more opioids than or anti-emetics than usual.  It is also important to recognize that 
PONV in this study increased after discharge from the PACU.  For patients who are admitted to 
the hospital after surgery, appropriate treatment will be provided for their PONV.  This would 
not be the case for patients admitted for their surgery as an outpatient, thus special attention to 
PONV when preparing discharge teaching for outpatients is crucial. Finally, the fact that 
smoking was not a predictor in orthopedic trauma patients, with a higher than average current 
smoking status, is worthy of further investigation. 
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Table 8:   Results of Univariate Logistic Regressions for PONV in 48 hours 
Variable Number and 
Percent 
PONV 
Odds Ratio Confidence 
Intervals  
p-value 
Male 
Female 
34 (43%) 
22 (71%) 
 
3.379 
 
1.384-8.247 
 
.007 
Smoker 
Non Smoker 
19 (41%) 
37 (56%) 
 
1.813 
 
0.846-3.885 
 
.126 
NO History of PONV 
History of PONV  
37 (42%) 
19 (79%) 
 
0.191 
 
0.065-0.558 
 
.002 
Age NA     0.984 0.956-1.014 .296 
Total Opioids/Wt NA 0.339 0.074-1.551 .163 
CYP2D6  
(Reference=Extensive 
Metabolizer) 
    Intermediate Metabolizer 
    Poor Metabolizer 
 
40 (56%) 
 
13 (38%) 
 
3 (42%) 
1.0 
 
0.581 
 
0.480 
NA 
 
0.121-2.790 
 
0.208-1.107 
NA 
 
.498 
 
.085 
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Table 9:  Multivariate Logistic Regression for PONV within 48 hours of surgery (n = 112) 
  
Odds 
Ratio 
95% Confidence Intervals   
  Lower Upper p-value 
 History of PONV 5.379 1.574 18.387 .007 
Gender .236 .084 .662 .006 
Smoking Status 1.359 .552 3.343 .505 
TotalOpioids+ .073 .005 1.046 .054 
CYP2D6 Extensive 
Metabolizer (REF)     1.000   
.012 
       Intermediate Metabolizer .492 .010 24.171 .721 
       Poor Metabolizer .026 .002 .288 .003 
Age .966 .931 1.003 .071 
CYP2D6 Extensive 
MetabolizerbyTotalOpioids 
(REF) 
    1.000   
.036 
    Intermediate Metabolizer    
by TotalOpioids+ 
4.616 .026 822.837 .563 
    Poor Metabolizerby 
TotalOpioids+ 
207.726 3.525 12240.875 .010 
     
+adjusted by weight 
 
 
 
 
85 
 
Figure 3:  Graph of means of total opioids and total ondansetron 
A graph of mean total opioids compared to a graph of the mean total ondansetron for the three CYP2D6 
classification groups. The three groups were significantly different in amount of opioids received (p=0.036) when 
analyzed by ANOVA. Though the groups were not statistically different for total doses of ondansetron (p=0.27), 
those subjects who required more opioids required less anti-emetic. 
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